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SUMMARY 
Pancreatic cancer (PDAC) is a deadly type of cancer with almost an equal amount of new cases 
and deaths observed yearly. It accounts for about 7% of cancer related deaths worldwide with 
less than 5% of PDAC patients living up to 5 years. The lack of specific and sensitive diagnostic 
tests is strongly responsible for this poor statistic. The discovery of differentially expressed 
genes and proteins associated with PDAC is crucial to elucidating this condition and may lead 
to biomarker finding and further understanding of the disease. This in turn may lead to 
improved diagnostic tests for early diagnosis. The aim of this study was to identify novel 
potential biomarkers for PDAC. 18 tissue samples (9 tumour and 9 normal) were obtained from 
PDAC patients at Chris Hani Baragwanath Johannesburg, South Africa during the Whipple 
procedure. Using focused gene arrays, differences in expression profiles of pancreatic tumours 
and cell line (MIA PaCa-2) were shown. Furthermore, RNA sequencing and antibody arrays 
were used for the identification of differentially expressed genes and proteins respectively. 
Utilizing multiple bioinformatics tools, functional enrichment, biomarker filtering, and variant 
analyses were performed. After discovery, novel potential gene biomarkers were then validated 
using real time PCR. Also, protein-protein interaction (PPI) analysis on potential biomarkers 
was done. In the current study, the overexpression of necrotic pathways was observed in 
tumours but not in normal and MIA-PaCa-2. Furthermore, differential gene and protein 
expression in tumour was shown. Functional enrichment analyses of the differentially 
expressed genes and proteins showed the upregulation of several pathways including: 
IGF/MAPK, Ras, and the immune system pathways. Importantly, JUP, ANGPTL4 and 
p27/kip1 were identified as novel potential biomarkers. Also, I have shown novel variants 
(SPARC, ZFHX3, TGM2 and COLIA1) predicted to result in loss of gene function. This study 
has identified novel potential biomarkers which can help in the diagnosis of PDAC. PPI 
analyses of these biomarkers indicate they may play important roles in inducing tumorigenesis. 
Information obtained from dysregulated signalling pathways and biological processes help in 
further understanding the biology of PDAC. Additionally, identified variations may enable 
tumour growth. In future, the identified novel potential biomarkers should be further validated 
in a larger sample number using easily accessible samples like blood. 
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CHAPTER 1- LITERATURE REVIEW 
1.1 Introduction 
1.1.1 The pancreas 
The pancreas is an organ of the digestive system. It is approximately 10 to 25 cm long with a 
flattened pear shape that stretches across the abdomen. Generally, the pancreas is divided into 
four regions; head, neck, body, and tail (figure 1.1). 
1. Head: The widest region of the pancreas and is found in the right side of the abdomen, 
sitting on the curve of the duodenum (first part of the small intestine). The head also 
has subdivisions: head proper and the uncinate process. Using the hand as an analogy 
the head proper is the palm whilst the uncinate process correlates to the pinkie and 
thumb. 
2. Neck: This is the region between the head and the body. 
3. Body: The mid region of the pancreas found between the neck and the tail. The vein 
and the superior mesenteric artery pass behind this region. 
4. Tail: Located on the left side of the abdomen (close to the spleen) and found at the end 
of the pancreas forming a thin tip. 
Importantly, 60-70% of Pancreatic ductal adenocarcinomas (PDAC)- the cancer of interest 
in this study- are found at the head of the pancreas while 20-25% are observed at the 
body/tail (Modolell et al., 1999). 
 
 
 
 
 
 
Figure 1.1: Diagram of the pancreas showing its four major regions- head, neck, body, and tail.     
Adapted from (Skandalakis et al., 2004.). 
Uncinate 
Process 
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1.1.2 Location of the pancreas 
The pancreas is situated at the back of the abdomen behind the stomach. Its location makes it 
difficult for early proper diagnosis of PDAC. Furthermore, the pancreas is surrounded by 
different blood vessels that supply blood to it and other neighbouring organs. This means that 
it is easy for PDAC to invade blood vessels thereby making treatment more difficult and 
complicated These blood vessels include the superior mesenteric artery, the celiac axis, the 
superior mesenteric vein, and the portal vein. The head of the pancreas can be seen at the 
interface between the early part of the small intestine and the stomach. The location of the 
pancreas at this interface is crucial as it can release digestive enzymes to partially digested food 
passing from the stomach into the and small intestine. Furthermore, this location is critical as 
it masks PDAC symptoms in the patient consequently leading to misdiagnosis at its early 
stages. 
1.1.3 Development of the pancreas 
The pancreas originates from the embryonic foregut. Embryonic development of the pancreas 
commences with the origination of the dorsal and ventral pancreatic buds. Both buds are linked 
to the foregut by ducts. The dorsal bud develops into the head, body, and tail while the ventral 
bud is responsible for the formation of the ucinate process. The rotation and fusion of dorsal 
and ventral pancreatic buds produces the pancreas.  
Differentiation of pancreatic cells occurs in 2 divergent pathways which giving rise to the 
endocrine and exocrine characteristics of the pancreas. In the exocrine pancreas, progenitor 
cells contain crucial molecules that initiate differentiation. These molecules include fibroblast 
growth factors, those of the Notch receptor system and follistatin. In PDAC, these molecules 
have been observed to be overexpressed.  This study seeks to identify more important 
molecules and pathways involved in pancreatic development that could be overexpressed 
during PDAC. NEUROG3 is expressed by endocrine progenitor cells facilitating the 
development of the endocrine pancreas region (Gradwohl et al., 2000). 
1.1.4 Regulation of pancreatic development 
A multipotent group of cells located in the foregut endoderm give rise to the pancreas, liver 
and biliary duct (Puri and Hebrok, 2010; Wandzioch and Zaret, 2009). In humans, the pancreas 
is first observed at four weeks of gestation as the dorsal bud emerging from the proximal end 
of the duodenum whilst in mice, the pancreas can be observed around E8.5 to E9.5. The 
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endocrine section consists of α, β, δ, ε and polypeptide cells that are arranged into islets. These 
cells produce the pancreatic hormones. Pancreatic development is strongly regulated with the 
exocrine and endocrine parts developing from the same progenitor cells. This regulation 
involves a coaction of Hedgehog signalling (Hebrok et al., 2000; Lau and Hebrok, 2010), Notch 
signalling, KRAS signalling and integrin signalling. These pathways are known to be 
dysregulated during PDAC and play a role in inducing tumorigenesis (Apelqvist et al., 1999; 
Esni et al., 2001; Murtaugh et al., 2003). Also, studies have described some transcription 
factors crucial for pancreatic development. These include: Pdx1 which is crucial for the 
stipulation of every pancreatic lineage (Gannon et al., 2000), NeuroD, ngn3, Pax4 and Hnf6, 
all contributing to propagation, differentiation and the commitment of endocrine lineage 
(Gannon et al., 2001; Offield et al., 1996). The differentiation of the exocrine lineage is 
influenced by both the absence of endocrine-favouring transcription factors and by the 
existence of permissive signals equipped by the adjoining pancreatic mesenchyme (Esni et al., 
2001).  
1.1.5 Pancreatic ductal cell lineage regulation during development 
Markers such as cystic fibrosis transmembrane receptor, cytokeratin19 (K19) carbonic 
anhydrase II (CA II), DBA lectin and transcriptional factors which include HNF1β, SOX9 and 
HNF6 are expressed by ductal cells. During pancreatic ductal development, the HNF6 plays an 
important role as HNF6-/- mice develop cysts in intralobular and interlobular pancreatic ducts 
(Pierreux et al., 2006). Also critical to pancreatic ductal formation is HNF1β, whose activation 
occurs downstream of HNF6 (Maestro et al., 2003) and is decreased in pancreatic cystic 
structures of HNF6-/- mice. Sox9, another crucial transcription factor, is responsible for the 
stimulation of proliferation and survival of progenitors thereby being critical for maintaining 
the pancreatic progenitor pool. The overexpression of these markers might play a crucial role 
in enhancing excessive cellular proliferation, consequently leading to carcinogenesis. 
(Seymour et al., 2007).  
1.1.6 Functions of the pancreas 
The pancreas is made up of the exocrine and endocrine gland. Both glands have different but 
critical functions. The exocrine pancreas is made up of 2 types of cells: acinar and duct cells. 
The acinar cells are responsible for the production of digestive enzymes. These enzymes 
include those that digest carbohydrate (amylase), proteins (trypsin and chymotrypsin) and fats 
(lipase). The enzymes are produced in their inactive forms to prevent the digestion of the 
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pancreas by them. The duct cells are responsible for the manufacture of fluids that combine 
with the inactive enzymes (proenzymes) to produce pancreatic juice. From the acinar cells, 
pancreatic juice flows into the duodenum. In the duodenum, the pancreatic juice then mixes 
with ingested food during its exit from the stomach. When pancreatic juice reaches the small 
intestine, it causes the proenzymes to be activated. Elevated amounts of bicarbonate in the 
pancreatic juice neutralize the acidic nature of the stomach.  
The endocrine pancreas contains millions of clustering cells called the Islets of Langerhans 
(Pancreatic islets). The pancreatic islets consist of 4 different cell types. Each of these cell types 
is responsible for the production of different hormones and play divergent roles. They include; 
(i) Alpha (α) cells secrete glucagon. The pancreas releases glucagon when there is a 
decrease in blood glucose levels. It increases the blood glucose levels by inducing 
the conversion of glycogen to glucose by the liver.  
(ii) Beta (β) cells which secrete insulin. Insulin is released as a response to elevated 
blood glucose levels. During increased blood glucose levels insulin is released and 
promotes the absorption of glucose into fats or glycogen in the liver or fats in 
skeletal muscles. 
(iii) Delta (δ) cells secrete somatostatin. Somatostatin is responsible for the regulation 
of α and β cells. It inhibits α and β cells from producing glucagon and insulin 
respectively when not needed. 
(iv) Gamma cells also referred to as pancreatic polypeptide cells act in the control the 
control of blood glucose levels by secreting glucagon and insulin when necessary. 
(v) Epsilon cells constitute about 1% of the entire islet cells. They secret ghrelin which 
play a role in stimulating hunger.  
1.1.7 Diseases of the pancreas 
Pancreatic cancer (the disease of interest in this study) is a lethal and aggressive cancer. It 
initiates when pancreatic cells begin to grow and proliferate uncontrollably.  
Exocrine tumours- They make up more than 95% of pancreatic cancer. These tumours begin 
in the exocrine cells that produce pancreatic enzymes which aid in digestion. Adenocarcinoma 
is the most prevalent of the exocrine tumours. When the tumour originates from the pancreatic 
ducts, it is referred to as pancreatic ductal adenocarcinoma (PDAC). PDAC constitutes 
approximately 90% of all pancreatic tumours making it the most frequently occurring one. Rare 
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types of exocrine tumours include acinar adenocarcinoma (tumours originating from acinar 
cells-cells responsible for the production of pancreatic juices), mucinous cystic tumours (that 
result fluid filled sacs or cysts in the pancreas), serous cystadenoma, colloid carcinoma, 
adenosquamous carcinoma, signet ring cell carcinoma, squamous cell carcinoma, solid and 
pseudopapillary tumours, hepatoid carcinoma, giant cell tumour and undifferentiated 
carcinoma (Herbst, 2016). 
Endocrine tumours- They are less common than exocrine tumours. They begin in the endocrine 
region of the pancreas which is responsible for the production of hormones like insulin and 
glucagon. These tumours are also referred to as islet cell tumours or pancreatic neuroendocrine 
tumours (PNETS). About one-third of these tumours produce hormones which can cause 
unusual symptoms. They are named per the hormone they produce: insulinomas (produce 
insulin), glucagonomas (produce glucagon), VIPomas (produce vasoactive intestinal peptide), 
gastrinomas (produce gastrin), PPomas (produces pancreatic polypeptide hormone) and 
somastostatinomas (produce somatostatin). Two-thirds of the endocrine tumours do not 
produce hormones or symptoms and are referred to as non-functioning tumours. Other rare 
types of pancreatic cancer include lymphomas, pancreatoblastomas and sarcomas (Herbst, 
2016). 
In this study, only tissue samples obtained from PDAC patients was utilized.  
1.1.8 Incidence of PDAC 
PDAC accounts for 2.8% of new cancer cases in USA and about 7% of cancer related deaths 
worldwide (Siegel et al., 2012). In developed countries, it is the 4th leading cause of cancer 
related deaths. Pancreatic cancer has an overall 5-year survival rate which remains below 5% 
(Ferrone et al., 2008). In the US, African Americans have the highest incidence rate compared 
to any other ethnic group followed by Ashkenazi Jews with Asians having the least incidence 
( Lynch et al., 2004).  
In South Africa, black males and females have the highest incidence rate, followed by 
Caucasians, Coloureds and Asians (National institute of occupational health, 2016). Due to the 
high incidence rate of pancreatic cancer (PDAC) amongst the black population, and thus ease 
of availability I have opted to use biological samples from this group only in this study.  
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1.1.9 Risk factors identified with PDAC 
Several risk factors have been associated with PDAC. These risk factor are important as they 
can be utilised in screening purposes for the screening of high risk groups. Risk factors include: 
Family history and inherited genetic disorders- Approximately 80% of pancreatic cancers 
occur sporadically but a small percentage is genetic and results from an inherited germ line 
mutation. Patients with a family history are 3 times more likely to develop PDAC (Fernandez 
et al., 1994). The most common inherited germ-line mutation in familial PDAC was identified 
as BRCA2 deleterious mutations (Murphy et al., 2002). Also, a germline point mutation was 
observed in PALB2 gene in 3% of familial PDAC patients (Jones et al., 2009). 
Smoking- Approximately 25% to 35% of PDAC cases have been linked to smoking making it 
a crucial risk factor (Lowenfels and Maisonneuve, 2004). It’s been suggested that smokers have 
a 1.74-fold risk of pancreatic cancer.  
Dietary factors- Acute alcohol consumption, consumption of meats and fatty foods and 
increased serum folate levels enhances the risk for developing PDAC. 
Pancreatitis- Chronic pancreatitis is responsible for up to 3% of PDAC cases (Lowenfels et 
al., 1999). Risk of developing PDAC ranges from 2.3% to 18.5% with patients suffering from 
chronic pancreatitis. 
Helicobacter pylori- Gastric colonization by H. pylori is the main cause of hyperacidity and 
gastric diseases and is implicated in PDAC (Trikudanathan et al., 2011). 
Obesity- This may lead to the formation of tumours through an abnormality in glucose 
metabolism, inflammation and hyperinsulinemia (Bracci, 2012). Diabetes: Obesity is often 
associated with type 2 diabetes which is associated with a doubling in the risk of PDAC. About 
1% of PDAC patients with early onset diabetes which manifests about 1-3 years develop 
PDAC. 
1.1.10 Signs and symptoms of PDAC 
One of the major reasons pancreatic cancer is difficult to detect and diagnose is that it is 
asymptomatic at its early stages. As the cancer matures signs and symptoms begin to appear 
but these are dependent on the type of pancreatic cancer and its location in the pancreas. 
Although symptoms occur, they could be non-specific and might appear and disappear. Also, 
PDAC symptoms can include those illnesses that are common and not severe, consequently, 
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patients are misdiagnosed several times.  Signs and symptoms include abdominal pain, weight 
loss, jaundice, nausea and vomiting, diabetes, fever and shivering as well as diarrhoea, 
anaemia, weakness and high blood pressure (Herbst, 2016). 
1.1.11 Diagnosis of PDAC 
PDAC is mostly diagnosed at its late stages. The doctor takes this following step for diagnosis: 
➢ Physical examination to check for any growth especially in the abdominal region. 
➢ Laboratory tests e.g liver function tests to check for bile blockage 
➢ Ultrasound, CT (computed tomography) scan and MRI (Magnetic resonance imaging) 
for detailed imaging of abdominal organs. 
➢ Biopsies, for example ERCP (Endoscopic retrogade cholangiopancreatography) in 
which a tube attached to a brush and a camera is passed through the mouth taking 
biopsies (Herbst, 2016). Other procedures include: percutaneous and EUS guided 
biopsies. 
In most cases, before these steps are done the cancer has progressed. This emphasizes the need 
for biomarkers (biological markers) present in easily accessible body fluids (like blood). This 
study seeks to identify novel potential biomarkers for the diagnosis of pancreatic cancer. 
1.1.12 Staging in PDAC 
Worldwide (y the American Joint Committee on Cancer) PDAC is grouped into stages from 
stage 0 to stage IV. They include: 
Stage 0: Tumour is located at superficial layers of the pancreatic ductal cells and has not spread 
outside the pancreas. These tumours can be referred to as pancreatic intraepithelial neoplasia 
III (PanIN III) or pancreatic carcinoma in situ. 
Stage I: Tumour has still not spread outside of the pancreas and is larger than 2cm. 
Stage II: Tumour is growing outside pancreas and has spread to the lymph nodes but has not 
spread into major blood vessels or nerves and distant sites 
Stage III: Tumour is growing outside pancreas and has spread to major blood vessels but not 
distant sites. 
Stage IV: Tumour has spread to distant sites such as lungs, liver and other surrounding organs 
and is therefore metastatic (Herbst, 2016). 
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In South Africa, PDAC is classified in 3 stages: 
Stage I: Tumour is resectable. This can also include borderline resectable tumours. 
Stage II: Tumour is locally advanced (non-metastatic). 
Stage III: Tumour is metastatic (Herbst, 2016).  
In this study, only stage I tumours were utilized since I was investigating the discovery of 
biomarkers for early diagnosis. 
1.1.13 Treatment options for pancreatic cancer 
Immediately after diagnosis of pancreatic cancer, the doctor needs to ascertain the stage of the 
tumour. That is, the size of the tumour and the degree of which it has spread must be 
determined. This assessment enables the doctor to decide on which treatment option to 
undertake. Treatment options are more effective when PDAC is diagnosed early, this again, 
emphasizes the need for biomarkers for early detection. Below are the pancreatic cancer 
treatment options available. 
1. Surgery- The type of surgery will depend size and location of the tumour, the patient’s 
wellbeing and how much the tumour has spread. The different types of surgeries that 
can be performed include; 
➢ Whipple procedure- This procedure is also referred to as pancreaticoduodenectomy and 
it is the most common type of surgery performed for the removal of tumours from the 
pancreas. In this case the surgeon removes the head of the pancreas, parts of the stomach 
called the pylorus and duodenum, gall bladder, distal common bile duct, and lymph 
nodes situated at the head of the pancreas. Thereafter the remaining part of the pancreas 
and digestive organs are reconnected to allow digestive enzymes, bile, and contents of 
the stomach to pass through into the small intestine during digestion. This surgery 
usually takes about 5-6 hours. 
➢ Distal pancreatectomy- This type of surgery is performed when the tumour is located 
at the body and tail of the pancreas. The surgeon proceeds to remove these parts 
including the spleen. 
➢ Total pancreatectomy- In this case the whole pancreas, parts of the stomach and small 
intestine, the spleen, bile duct and neighbouring lymph nodes are removed. 
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Neoadjuvant therapy includes the use of fluorouracil and adjuvant therapy could be 
gemcitabine or fluorouracil based. Adjuvant therapy increases survival of patients that have 
underwent surgery.  
2. Chemotherapy- This treatment option requires the use of drugs to kill the tumour. Side 
effects may vary depending on the drug and patient. Gemcitabine is a widely used 
chemotherapeutic drug for pancreatic cancer. Lack of efficacy of gemcitabine and other 
chemotherapeutic agents is problematic (Lopez-Casas and Lopez-Fernandez, 
2010).Other widely used chemotherapeutic agents include: 5- Fluorouracil and 
Folfirinox. 
3. Radiotherapy- This treatment uses energy rays to kill the tumour. Radiation is directed 
to the abdomen region by a machine called the Linear accelerator (LINAC). Side effects 
may include vomiting, nausea, diarrhoea and indigestion. 
In some cases, the tumour cannot be removed completely, for example, if the tumour blocks 
the small intestine or common bile duct. This situation requires the surgeon to create a bypass 
that allows fluid to pass through the digestive tract.  
 
1.2 Discovering biomarkers of PDAC 
At the early stages of pancreatic cancer, it is usually misdiagnosed due to the lack of efficient 
diagnostic tests and the similarity of its symptoms to other more common ailments. Early 
diagnosis is critical for increasing survival rates for patients with PDAC; making the discovery 
of biomarkers urgent. The characteristics of an ideal biomarker includes, being able to provide 
prognostic and predictive information in order to help guide decisions of clinicians and to 
provide adequate information on the progression of the disease (Pepe et al., 2008). It can also 
be used to assess efficacy of treatment administered to a patient over a period. Also, a good 
biomarker should be expressed in bodily fluids especially in the blood. This makes for patients 
to be diagnosed without any need for invasive procedures. Furthermore, a biomarker must be 
very specific and sensitive for the disease condition. Over the years several potential 
biomarkers of pancreatic cancer have been discovered and studied using various techniques 
such as transcriptomics, metabolomics, and proteomics but most have not passed validation as 
they lack adequate sensitivity and specificity. Appendix A1-A5 contains some potential 
biomarkers discovered over the years. Amongst them is the most widely studied, CA 19-9. CA 
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19-9 is being used mainly in assessing prognosis and in the monitoring of patients under 
therapy but has disadvantages. CA 19-9 is elevated in several other cancers including 
hepatocellular, colorectal and oesophageal. It has also been shown to be increased in several 
other diseases including pancreatitis. Its non-specificity makes it unsuitable for diagnosis and 
screening of pancreatic cancer. Additionally, CA-19-9 is not expressed in patients lacking 
Lewis antigen and thus cannot be used to diagnose this group (Chan et al., 2013). These 
disadvantages hint for the discovery of specific and sensitive biomarkers for the diagnosis of 
early asymptomatic PDAC. 
1.2.1 Gene expression profiling (Transcriptomics) in PDAC 
Gene expression profiles vary across individuals and population groups. Approximately 83 % 
and 17% of genes have been observed to be differentially expressed amongst individuals and 
populations respectively (Storey et al., 2007). This hints for gene expression studies to be 
conducted amongst several population groups. The emergence of high-throughput genomic 
technologies has enabled gene expression profiling in pancreatic cancer studies. These studies 
have allowed different groups to pursue the discovery and validation of biomarkers for the 
early detection (diagnostic) and classification of PDAC. Furthermore, these technologies might 
help to identify novel therapeutic targets for pancreatic cancer treatment (Lopez-Casas and 
Lopez-Fernandez, 2010). Analysing the gene expression profiles aids the description of how 
genes react to pancreatic cancer progression and this helps in the formulation of preliminary 
hypothesis regarding the disease condition. Using various techniques, researchers can identify 
differentially expressed genes by comparing normal pancreatic gene profiles to their cancerous 
counterparts. One of the first published studies used the serial analysis of gene expression 
(SAGE) technique to analyse thousands of transcripts using bulk tissues obtained from 
pancreatic cancer patients (Argani et al., 2001). The study identified mesothelin as being 
overexpressed in most PDAC tissue samples making it a putative marker. One major problem 
observed in pancreatic cancer studies involving gene expression profiling of bulk tissues is 
extracting good quality RNA. Therefore, stringent RNA extraction techniques must be utilized 
to achieve this. 
Grutzmann et al. performed one of the first meta-analyses studies in which they profiled genes 
involved in PDAC. 568 genes were identified to be significantly up/down regulated during 
PDAC (Grutzmann et al., 2005). This study uniquely identified more genes dysregulated during 
pancreatic cancer as only 22% were previously described in published literature. Jones and his 
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colleagues provided comprehensive work in which they integrated genomic and transcriptomic 
(SAGE) data. They showed essential signalling pathways and biological processes occurring 
in many pancreatic cancers. These pathways include Wnt/Notch signalling, KRAS signalling, 
TGF-β signalling, regulation of invasion, DNA repair, small non-KRAS GTPase-dependent 
signalling, homophilic cell adhesion, c-Jun N-terminal kinase signalling, Hedgehog signalling, 
regulation of G1/S phase transition and integrin signalling (Jones et al., 2008a). The authors 
claim that the identification of several core pathways indicates the involvement of many genes 
in PDAC and this hints to pancreatic cancer progression might be patient specific. This point 
of view encourages the need for personalized medicine in the treatment of PDAC. 
Nevertheless, in the discovery of biomarkers for prognostic, diagnostic, disease staging and 
monitoring treatment outcomes, gene expression profiling will help. 
Diagnostic biomarkers aid in the early detection of disease and enable for appropriate treatment 
to be administered. The early detection of PDAC is crucial as it increases the chances of 
survival in patients. Over the years, gene expression profiling has been used for the discovery 
of novel potential biomarkers. One study on IPNM (Intraductal papillary mucinous neoplasm), 
a PDAC precursor lesion, samples utilizing microarrays revealed four genes (GAS6, GPC1, 
CAV1 and CYR61) that were differentially expressed and proposed as potential biomarkers 
(Terris et al., 2002). In another study using microarrays, Buchholz and colleagues identified 30 
differentially expressed genes occurring in PDAC. Amongst these genes are, S100P, IF127, 
IL-13RA1 and RABAC1 all of which were significantly upregulated (Buchholz et al., 2005). 
S100P has been further used in some cases as a diagnostic biomarker (Deng et al., 2008). 
Although, several studies have identified potential biomarkers (like S100P), they fail to pass 
validation experiments. This failure is mostly attributed to lack of specificity and sensitivity to 
pancreatic cancer. 
Prognostic biomarkers help determine the progression of PDAC and gene profiling helps 
identify these markers. Using SW1990 (a pancreatic cancer cell line) and SW1990HM (a liver 
metastasized pancreatic cancer clone), 40 genes were shown to be involved during pancreatic 
cancer associated liver metastasis. Campagna and colleagues did a comparative study of stage 
4 and stage 2/3 pancreatic cancers and observed 173 genes dysregulated between the two 
groups (Campagna et al., 2008). Amongst these genes, four were further validated using real-
time PCR but only MXI1 was confirmed as upregulated in stage 4 compared to stage2/3. 
Further validation studies on the use of MXI1 as a prognostic marker is yet to be conducted. 
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Although a good amount of work has been done to identify prognostic biomarkers of pancreatic 
cancer, a lot more must be done to identify better predictors of prognosis. 
1.2.2 Protein expression profiling (proteomics) in pancreatic cancer  
Several studies have indicated that although genomic level mutations can affect protein 
structure and function, mRNA expression does not correspond to protein expression(Pan et al., 
2013). Furthermore, although investigations into mRNA expression levels help provide a better 
understanding of any disease, they do not accurately correspond to progression of the ailment. 
Protein profiles however provide a more accurate understanding of disease states and 
progression (Grantzdorffer et al., 2008). Also, crucial signalling molecules in important protein 
molecules cannot be identified by studying mRNA expression profiles.  
Studying the protein expression profiles in diseased conditions such as cancer has become 
critical in elucidating the initiation and progression of such diseases. Proteins are essential 
biomolecules for the induction and regulation of biological processes. In cancer studies, focus 
is mostly on the identification of important proteins, protein interactions and significant 
pathways involved in tumorigenesis. Proteomics enable the analysing of the whole proteome 
of a cell, tissue, body fluids and organs. It facilitates the understanding of the structure and 
function of crucial proteins (Baak et al., 2003; Grantzdorffer et al., 2008). Also, proteomic 
tools are beneficial for the discovery of novel potential biomarkers and therapeutic targets in 
pancreatic cancer treatment. Recent proteomics studies using varying sample types- serum, 
tissue, pancreatic juice, pancreatic cancer cell lines-, have identified some proteins 
differentially expressed during PDAC. However, they still lack the specificity and sensitivity 
to adequately detect PDAC in asymptomatic patients (Chen et al., 2005a).  
Proteomic studies have revealed some potential diagnostic and prognostic biomarkers of 
PDAC. Table A3 provides a list of these potential biomarkers including the various proteomic 
technologies utilized for their discovery. One of the first published studies on the discovery of 
protein biomarkers for pancreatic cancer utilized immunoassays. These studies identified CEA 
and  CA-50 as potential biomarkers (Haglund et al., 1987; Molina et al., 1990). Furthermore, 
mass spectroscopy is one of the most utilized technologies for the discovery of protein 
biomarkers. Some of the biomarkers identified using this method include; galectin-1, gelsolin, 
lumican, cathepsin D, plectin-1, moesin, cofilin, (Chen et al., 2005b; Lu et al., 2004; Shen et 
al., 2004), pancreatic lipase related protein-1, pre-proprotein and serine proteinase-2 (Gao et 
al., 2010). More recently, Glypican 1 was identified as a potential biomarker for pancreatic 
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cancer (Melo et al., 2015). Enzyme-linked immunosorbent assays (ELISA) have also been used 
for protein biomarker discovery in pancreatic cancer studies. Some of the potential biomarkers 
identified using ELISA include Cytokeratin 18 (Dive et al., 2010) and serum REG4 (Takayama 
et al., 2010). To determine the efficacy of these potential biomarkers, they would have to be 
independently tested multiple times using large number of samples obtained from PDAC 
patients. 
Protein-Protein interaction (PPI) networks- Role in pancreatic cancer research 
Most proteins carry out their functions within an intricate network consisting of other proteins. 
One component within this network can affect many others. The upregulation or 
downregulation of a protein might result to more or lesser connections being made. This 
consequently might lead to the initiation and propagation of pathological conditions (1). PPI 
networks help to understand functions of recently discovered proteins of interest or provide 
clue of new functions for already known ones (Sevimoglu and Arga, 2014) . These networks 
also aid to identify protein sets within its environment and discovers known/predicted 
interactors. Furthermore, they help to identify biological processes, pathways and protein 
domains enriched within the network (Dai et al., 2015). The analysis of these enriched 
pathways and biological processes help to elucidate disease conditions.  
PPI network analysis have been applied to a few pancreatic cancer studies. Yuan and colleagues 
constructed a large network utilizing information from protein-protein interactions (Yuan et 
al., 2015). They then used a shortest part method to mine 13 novel genes involved in pancreatic 
cancer. They proposed that these genes might have therapeutic benefits and as future drug 
targets. In their gene expression analysis of normal and cancerous pancreatic tissues, Long et 
al., used PPI network analysis to predict effectively protein interactors, biological processes 
and pathways in which their differentially expressed genes were enriched (Long et al., 2016). 
PDAC is a disease whose aggressive progression is still poorly understood, PPI network 
analysis might help to further elucidate it. 
1.2.3 Alternative splice variants as biomarkers of PDAC 
Alternative splice variants are promising for use as biomarkers for PDAC (Omenn et al., 2010). 
They have been identified to be common all over the human genome. Alternative splicing 
enables a gene to give rise to multiple proteins. Splice variants that affect the protein coding 
region of the mRNA results in proteins with aberrant structure and function. Alternative splice 
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variants affect gene regulation and/or structure of proteins (Hartel et al., 2008; Omenn et al., 
2010). Splice variants are generally stable and can be quantified. 
Using exon array analysis, splicing variants associated with cancers of the bladder, colon and 
prostrate have been identified at the mRNA level (Thorsen et al., 2008). These variants are 
observed to have both diagnostic and prognostic consequences. Hayes and colleagues 
postulated the use of splice variants as potential biomarkers of pancreatic cancer (Hayes et al., 
2007). Carrigan and colleagues utilized spliceoform-specific microarrays and PCR to identify 
28 genes encoding spliceosomal proteins that are underexpressed during pancreatic cancer 
(Carrigan et al., 2011). Also, abnormal expressions of AP-2α have been identified in pancreatic 
cancer. Using RT-PCR (for gene level analysis), immunofluorescence and western blotting (for 
protein level analysis), Carriere and colleagues showed that various isoforms of AP-2α are 
expressed in multiple pancreatic cancer cell lines (Carriere et al., 2011). Amongst these 
isoforms identified was AP-2α variant 6 which seemed to pancreatic cancer specific. 
Furthermore, using similar techniques as Carriere et al., Arafat and colleagues identified 
alternative splicing in various tumour specific exons of stromal COL6A3. They postulate that 
the resulting spliced proteins might be involved in the initiation and development of pancreatic 
cancer and serve as potential biomarkers. 
1.2.4 Signalling Pathways altered during PDAC 
The importance of signalling pathways in the elucidation of tumour progression has been 
identified (Hanahan and Weinberg, 2000; Vogelstein and Kinzler, 2004). The study of 
pathways involved in tumour progression helps in understanding the disease (Chittenden et al., 
2008; Edelman et al., 2008; Lin et al., 2007). During pancreatic cancer, genes involved in core 
signalling pathways are altered. These alterations consequently lead to the progression of 
pancreatic cancer.  
Jones and colleagues have identified 12 core signalling pathways in which some genes are 
altered during pancreatic cancer (Table 1.1), although there was no shown certainty that all the 
altered genes play functional roles (Jones et al., 2008a).  
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Table 1.1: Pathways and regulatory processes genetically altered in pancreatic cancer. 
Pathway or regulatory process Some altered genes 
Wnt/Notch signalling TCF4, GATA6MYC, PPP2R3A, TSC2, MAP2, 
WNT9A 
KRAS signalling KRAS, RASGRP3, MAP2K4 
Hedgehog signalling CREBBP, TBX5, LRP2, SOX3, GL13, GL11, 
BOC, BMPR2 
DNA damage control TP53, EP300, ERCC6, ERCC4, RANBP2 
Regulation of G1/S phase transition APC2, CHD1, FBXW7, CDKN2A 
Homophilic cell adhesion CDH1, CDH7, CDH10, PCDH17, PCDH9 
Integrin signalling LAMA1, LAMA4, LAMA5, ILK, FN1, ITGA4, 
ITGA11 
Regulation of invasion DPP6, PCSK6, APG4A, PRSS23, ADAM11, 
ADAM12, ADAMTS15 
TGF-β signalling SMAD4, SMAD3, BMPR2, TGFBR2 
Epidermal growth factor receptor (EGFR) ErbB-2, ErbB-1, ErbB-4 
NF-kB Rel A, RelB, c-Rel, P100/p52 
Small GTPase-dependent signalling RP1, PLCB4, DEPDC2, PRKCG, AGHGEF7, 
CDC42BPA 
Source: Adapted from (Jones et al., 2008a) 
Furthermore, Waddell and colleagues performed whole genome sequencing and copy number 
variation analysis using 100 PDAC samples. They observed chromosomal arrangements 
leading to the disruption of key genes (TP53, CDKN2A, SMAD4, ROBO2, and ARID1A) that 
are crucial to pancreatic cancer (Waddell et al., 2015). They also identified structural variations 
in novel drivers of pancreatic tumorigenesis (PREX2 and KDM6A).  Most of these variants 
identified were duplications, deletions, inversions, and chromosomal arrangements. The most 
frequently identified genetic alterations are those of K-Ras, Tp53, CDKN2A, BRCA2 and 
DPC4(Jones et al., 2008b). Mutations of the K-Ras gene are known to initiate tumour growth 
in the pancreas. This is then followed by a loss mutations of p16, Tp53 and  SMAD4 (Polireddy 
and Chen, 2016). These alterations result in the suppression of apoptosis, induction of cellular 
proliferation and the enhancement of tumour invasion & metastasis (Korc, 1998). Studies 
identifying more genetic alterations are crucial in further elucidating the progression of PDAC. 
The overexpression of growth factors in signalling pathways have been observed in pancreatic 
cancer cell lines. These growth factors include; Epidermal growth factor (Korc et al., 1986), 
fibroblast growth factor (Kornmann, 1997) and platelet derived growth factor (Weissmueller 
et al., 2014). However, studies with pancreatic tumours are necessary to corroborate these 
findings. 
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1.3 Justification of study 
Pancreatic cancer (PDAC) accounts for 2.8% of new cancer cases and about 7% of cancer 
related deaths worldwide (Siegel et al., 2012). In the United states, it is projected to be the 2nd 
leading cause of cancer-related deaths by 2030 (Polireddy and Chen, 2016). PDAC is usually 
diagnosed at late stages which is responsible for its low survival rate. This emphasizes the need 
for biomarkers that can detect PDAC at asymptomatic stage. Profiling genes and proteins that 
play a role during pancreatic cancer provide a good way to identify novel potential biomarkers 
to aid in the early diagnosis of pancreatic cancer. Previous studies have identified potential 
biomarkers for pancreatic cancer, however, the challenge for lack of sensitivity and specificity 
to detect early stage PDAC is still prevalent. This study seeks to overcome this challenge in 
four major ways. First, in using stringent sample handling and processing techniques to retain 
integrity of samples. This is crucial as poor sample quality can be responsible for misleading 
and/or non-reproducible results. Second, by utilizing both transcriptomic and proteomic 
discovery methods. This gives us a broader pool of candidates to analyse for biomarker 
discovery. Third, with the use highly sensitive, specific, and high throughput gene and protein 
expression methods which include focused array panels and next generation sequencing. These 
highly sensitive methods reduce the occurrence of false positive results and enable the detection 
of low quantity occurring gene/proteins. Pathway arrays enabled for cancer-focused analyses 
and the identification of dysregulated biological processes/pathways.  Fourth, by employing an 
array of bioinformatics tools, for example, the Ingenuity pathway analysis (IPA) biomarker 
filtering tool help to identify only the best candidate biomarkers relevant to PDAC. 
Furthermore, this study also uniquely utilizes samples from a black African population. It has 
been observed that approximately 17% of genes vary within populations (Storey et al., 2007), 
as there is currently no published PDAC gene expression data from any African population, it 
is pertinent to conduct this study. 
1.4 Aim 
The overall aim of this study was to identify novel potential biomarkers of pancreatic cancer. 
1.5 Objectives 
1. Comparative focused gene expression profiling of pancreatic tumours and cell line 
(MiaPaca-2) using RT2 Profiler PCR arrays to identify differentially dysregulated pathways. 
17 
 
2. Transcriptome profiling of pancreatic tissues (tumour and normal) using RNA sequencing 
to identify differentially expressed genes and dysregulated pathways.  
3. Gene biomarker discovery using Ingenuity pathway analysis tool to identify potential 
biomarkers. 
4. Protein-protein interaction network analysis of potential gene biomarker using STRING 
software. 
5. Validation of potential gene biomarkers using real-time PCR. 
6. Genetic variant discovery using Ingenuity variant analysis tool.  
7. Focused protein expression profiling of pancreatic tissues (tumour and normal) using 
antibody arrays to identify differentially expressed proteins and dysregulated pathways. 
8. Protein biomarker discovery using Ingenuity pathway analysis tool to identify potential 
biomarkers. 
9. Protein-protein interaction network analysis of potential protein biomarker using STRING 
software. 
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CHAPTER 2- METHODS 
2.1 Materials 
All materials including kits, reagents, instruments, and software used in this study can be found 
in the appendix section (Tables A15- A18) 
2.2 Methods 
2.2.1 Summary of experimental strategy 
Except for sample collection, sample storage, RNA sequencing and differential gene 
expression analysis, every method utilized was done by me. Tissue samples (normal and 
tumour) were obtained from black South African pancreatic cancer patients at Chris Hani 
Baragwanath hospital, Johannesburg, South Africa by means of the Whipple procedure. 
Samples were processed (as described in Section 2.2.3) and total RNA and protein were 
extracted (see 2.2.4) from tissues. The Human cancer PathwayFinder RT2 Profiler PCR array 
– a focused pathway analysis platform- was then used for gene expression profiling of tissue 
samples. The Human Cancer PathwayFinder RT2 Profiler PCR array was also used to compare 
the gene expression profile of tissue samples to that of a widely used pancreatic cancer cell line 
(MIA PaCa-2).  After obtaining differentially expressed genes (DEGs) in tissue samples and 
the cell line, functional enrichment analyses were performed to identify dysregulated pathways. 
Furthermore, RNA sequencing was performed using tissue samples and differentially 
expressed genes (DEGs) obtained. Utilizing a range of bioinformatics tools (Table 2.3), 
functional enrichment analyses were then performed on DEGs obtained from the RNA 
sequencing. Also, variant and biomarker filtering analyses were achieved using the Ingenuity 
variant analysis and Ingenuity pathways analysis tools respectively. Having identified novel 
potential biomarkers (from the biomarker filtering analysis), real-time PCR was used for 
preliminary validation studies. Additionally, the Human Oncology Proteome profiler array – a 
focused proteomic platform- was used for protein expression profiling of tissue samples. 
Differentially expressed proteins were observed and functional enrichment analysis performed. 
Biomarker filtering analysis was then performed to identify novel potential protein biomarkers. 
The protein-protein interaction network analyses of identified biomarkers were also done using 
STRING software. 
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Figure 2.1:  Flowchart of methods undertaken in the study. 
2.2.2 Ethics statement and Funding 
The Human ethics committee of the University of Witwatersrand, Johannesburg, South Africa, 
approved the collection of biological samples from pancreatic cancer patients (Ethics clearance 
certificate number- M150778). The Director of Chris Hani Baragwanath Johannesburg, South 
Africa also approved sample collection on behalf of the hospital board of directors. Patients 
were required to sign consent forms (included in ethics application).  
The Medical Research Council of South Africa provided funding for most of this study. Dr 
John Devar also made funds to be available for RNA sequencing. There was no conflict of 
interest. 
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2.2.3 Sample collection, storage, and processing 
A total of 9 (nine) patients were used for this study (see Table A14 for information). A total of 
18 tissues (9 tumour and corresponding normal tissues). All tissues were obtained from black 
South African pancreatic cancer patients undergoing Whipple procedure at Chris Hani 
Baragwanath Johannesburg, South Africa. Procedure was conducted by Drs Martin Brand, 
Omoshoro Jones, and John Devar. Samples were collected and stored by staff at the 
Department of Surgery, University of Witwatersrand. Tissues of about 20-50 mg were then 
transferred into 1.5 ml cryotubes containing about 1 ml RNAlater RNA stabilization reagent. 
Biopsies were kept at 4°C overnight and then stored at -70°C till it was ready to be processed. 
Tissue samples stored using RNAlater are stable for 1 week at 25°C, 1 month at 4°C and 1 
year at -70°C. 
 
Sample homogenization. 
Tissues 
For gene expression profiling using the Human Cancer PathwayFinder RT2 Profiler PCR 
arrays, 1 normal and 2 tumour tissue samples were used. 30 mg of each tissue sample was 
homogenized in 600 µl of lysis buffer (provided in the Qiagen Allprep DNA/RNA Mini kit) 
using a TissueRuptor. The lysate was then centrifuged for 3 min at maximum speed.  
For gene expression profiling using RNA sequencing, samples from 2 patients (patients 1 and 
2) was used. From each patient 1 tumour and corresponding normal tissue was obtained, that 
is, 2 normal and 2 tumour samples (same samples used for the Human Cancer PathwayFinder 
RT2 Profiler PCR arrays) were used. Homogenization was performed as previously described. 
For Validation of potential gene biomarkers using real- time PCR, samples from 5 patients 
(patients 3,4,5,6 and 7) was used. From each patient 1 tumour and corresponding normal tissue 
was obtained, that is, 5 normal and 5 tumour samples (different samples from the ones 
previously used) were utilized. Homogenization was performed as previously described. 
For proteomic profiling using the Proteome profiler arrays, 3 normal and 3 tumour tissues 
(patients 6,8 and 9) were used. 40 mg of tissue was placed in lysis buffer (0.5% igepal, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulphate, 150 mM sodium chloride and 50 mM 
Tris-HCL (pH 7.5) containing a protease inhibitor cocktail of Aprotinin (0.5 µg/ml) and PMSF 
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(1 mM). Tissues were then homogenized using TissueRuptor and centrifuged at 2000 xg for 
10 mins at 4°C. 
Cell Culture 
For this study, we used the pancreatic cancer cell line, MIA PaCa-2, which was obtained from 
a 65-year-old Caucasian male. Pancreatic cancer cells (MIA PaCa-2) were cultured with 10% 
FBS in DMEM and 1% penicillin-streptomycin. For RNA extraction, media was carefully 
removed from flask and adherent cells washed with 1 ml 1X PBS.  Cells were trypsinized to 
detach adherent cells using 700 µl of Trypsin-EDTA. Fresh media was then added to resuspend 
cells. Resuspended cells were transferred to 15 ml tubes and centrifuged at 1000 xg for 5 mins 
to pellet cells. The supernatant was carefully discarded and 350 µl of Buffer RLT Plus 
(provided in the Qiagen Allprep DNA/RNA Mini kit). The cells were then lysed by pipetting 
up and down severally. 
2.2.4 Total RNA and Protein isolation 
Total RNA isolation 
Total RNA was extracted using the Qiagen Allprep DNA/RNA Mini kit and procedure 
performed following the manufacturer’s instruction. 
DNase Digestion 
This was done using a DNase kit. The kit contains a 10X Reaction buffer, DNase 1 and stop 
solution. 5 µl each of 10X Reaction buffer and DNase 1 was added to 50 µl of RNA sample. 
The combination was gently mixed and incubated for 15 mins at room temperature. 5 µl of stop 
solution was then added to bind magnesium and calcium ions thereby inactivating DNase 1. 
The mixture is then heated at 70°C for 10 mins and then chilled on ice. 
RNA quantification and purity assessment 
After DNase digestion, Total RNA was quantified using the NanoDrop spectrophotometer. A 
ratio of absorbance at 260 nm and 280 nm of above 1.8 was observed in every sample. 
Furthermore, an RNA agarose gel was run for each sample to ascertain integrity. 
RNA Agarose gel electrophoresis 
A sterile 500 ml beaker was placed in a fume hood and 1.95 g agarose, 108.23 ml RNase free 
water, and 13 ml 10X MOPS added. The mixture was boiled in a microwave until dissolved 
completely. 8.78 ml formaldehyde and 6.5 µl ethidium bromide were then added to the 
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dissolved mixture in a fume hood. Once the mixture cooled, it was poured into a gel tray with 
comb already inserted. The mixture took about 20 mins to solidify. While gel was solidifying 
the running buffer (1 X MOPS) and loading samples were prepared. For a 20 µl sample, 2 µl 
of RNA loading dye was added. This made up the loading samples. After the gel had solidified, 
the comb was carefully removed. The running buffer was poured into the gel tank and the gel 
placed inside. Samples were then loaded into the wells and the gel covered. Gel tank was 
plugged into a power supply and voltage set at 100 V. After about 120 mins the gel was viewed 
using a Gel Doc TM XR+ imager to observe RNA. 
Protein Extraction 
The supernatant obtained from the tissue sample homogenization technique was transferred 
into a new tube. For each sample 10 µl was transferred for a new tube to be used for protein 
quantification. The remaining samples were stored at -70°C for proteome profiling assays. 
Protein quantification 
Protein quantification was performed using the Quick start™ Bradford protein assay kit. 20 µl 
of the standard (BSA 2 mg/ml) and unknown samples were pipetted into 1 ml cuvettes.  1 ml 
of the 1X Dye reagent was then added and mixed repeatedly. The mixture was then incubated 
at room temperature for 10 mins. The spectrophotometer was set to 595 nm and blanked using 
a mixture of 20 µl water and 1 ml of 1X Dye reagent. The absorbance of standard and unknown 
samples at 595 nm were measured. A standard curve was created by plotting the absorbance 
values at 595 nm values (y-axis) versus their concentrations in µg/ml (x-axis). The unknown 
sample concentrations were then determined from the plot. 
 
2.2.5 cDNA First strand synthesis 
The RT2 First strand kit was used in the synthesis of cDNA from mRNA in the total RNA. A 
genomic elimination mix was prepared by adding 2 µg of RNA, 2 µl of Buffer GE and RNase 
free water to a total volume of 10 µl. The mix was then incubated for 5 min at 42° C and then 
placed immediately on ice for at least 2 mins. Afterwards the reverse transcription mix was 
prepared. For 1 reaction, this mix included 4 µl of 5X Buffer BC3, 1 µl Control P2, 2 µl of 
RE3 Reverse Transcriptase Mix and 3 µl RNase-free water to make a total volume of 10 µl. 
The reverse transcription mix and genomic DNA mix were combined and incubated at 42°C 
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for 15 mins and then 95°C for 5 mins. 91 µl of RNase-free water was then added and the mix 
stored at -20°C until when needed. 
2.2.6 Focused gene expression profiling using the Human Cancer PathwayFinder RT2 
Profiler PCR Arrays 
Brief description of kit  
This is a reliable and sensitive technology for gene expression profiling. It can be used in 
analysing concentrated panels of genes involved in pathways, biological processes, and signal 
transduction with the use of real-time PCR. In this study, the Human Cancer PathwayFinder 
RT2 Profiler PCR Array was utilised. This array contains 84 genes involved in various 
pathways- Angiogenesis, Apoptosis, Cell cycle, Cellular senescence, DNA Damage& Repair, 
Epithelial-to-Mesenchymal Transition (EMT), Hypoxia signalling, Metabolism and Telomeres 
& Telomerases- that have been identified or suspected to be involved in carcinogenesis. The 
96-well array also contains 5 housekeeping genes, 1 human genomic contamination control, 3 
reverse transcription controls and 3 positive PCR controls. Each 96-well plate contains SYBR® 
green optimized primer assays for a thoroughly researched pathway focused panel of genes. 
This allows for simplicity, high sensitivity and specificity in gene expression study and 
analysis. 
Procedure 
For each array, the PCR components mix was first prepared by adding 1350 µl of 2X RT2 
SYBR Green Mastermix, 102 µl of cDNA synthesis reaction and 1248 µl of RNase-free water 
to a sterile 5 ml tube. Using the Integra 8-well multi-pipette, 25 µl of the mix was dispensed in 
each of the 96-well in the array. The array was then tightly sealed using an optical adhesive 
film and centrifuged for 1 min at 1000 g at room temperature. The array was then placed in the 
real-time cycler machine. The cycling condition was set as follows: 95°C for 10 min (1 cycle), 
95°C for 15 secs (45 cycles) and 60°C for 1 min (45 cycles). At the end of the cycles the Cp 
values were obtained to be used for analysis. 
Data analysis 
The Qiagen RT2 Profiler PCR array analysis software was used to generate differentially 
expressed genes. Data obtained from the Roche LC-480 was uploaded onto Microsoft excel. 
This data was then carefully arranged into adequate columns and rows as instructed on the 
website and further uploaded for analysis.  Also, to identify novel potential biomarkers, manual 
filtering was performed using genes upregulated in both tumour tissues and MIA PaCa-2 cell 
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line. Manual filtering involved going through the pancreatic cancer databases. Furthermore, 
the Reactome software was used (Croft et al., 2011) to indicate pathways in which the identified 
genes of interest were enriched. Reactome is a peer-reviewed database that allows for data sets 
to be mapped, assigned pathways and overrepresentation analysis performed. 
2.2.7 Gene expression profiling using RNA sequencing 
Brief description of RNA sequencing 
RNA sequencing uses deep sequencing technology for profiling the transcriptome. RNA 
sequencing is known to provide much more accuracy in the detection and measurement of 
transcripts compared to other methods (Wang et al., 2009). Interestingly, RNA sequencing can 
also reveal sequence variation which makes it an exciting tool for gene expression studies. 
Procedure  
RNA sequencing was done by Inqaba-biotec, South Africa. Total RNA was extracted from 
tissue samples and DNase digestion performed as previously described. Total RNA for each 
sample was sent to Inqaba-biotec for further processing, sequencing, and differential gene 
analysis.  
Library preparation included the depletion of ribosomal RNA (rRNA) from total RNA samples 
which was done using rRNA reduction library kit (IB Miseq RNA-0). The rRNA depleted RNA 
was then converted to complimentary DNA and 150 bp sequenced. Sequencing was done using 
the Illumina miSeq (which can perform up to 2 X 300 paired-end reads in a single run). Read 
numbers were obtained for each sample (Table 2.1). The CLC genomics workbench software 
was used for data normalization and differential gene analysis. 
Table 2.1: Number of reads obtained per sample 
Sample Number of reads 
Tumour patient 1 263325 
Tumour patient 2 154409 
Normal patient 1 1504525 
Normal patient 2 964390 
 
Data analysis 
Differential gene analysis 
The CLC-BIO genomics workbench (www.qiagenbioinformatics.com/products/clc-genomics-
workbench) was used for differential gene expression analysis following the procedure shown 
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available at                        
http://resources.qiagenbioinformatics.com/manuals/clcgenomicsworkbench/current/index.php
?manual=RNA_Seq_analysis.html. HG19 was used as the reference genome.  
Functional enrichment analysis 
The Morpheus software was used to generate a heat map of the observed differentially 
expressed genes. The PANTHER version 6 (Mi et al., 2007) was then used for functional 
enrichment analysis of identified upregulated genes.  PANTHER enabled the identification of 
molecular functions, biological processes, and pathways in which upregulated genes were 
enriched. For this enrichment analysis, our cut off was a p-value of 0.05. Furthermore, FunRich 
(Pathan et al., 2015) was used to observe gene interaction network, protein domains, 
transcription factors, clinical phenotypes in which upregulated genes were enriched.  
The DAVID tool (Huang et al., 2007) for functional enrichment analysis of downregulated 
genes and the GeneMania tool used to identify gene interaction networks. 
2.2.8 Biomarker filtering analysis  
The Biomarker filtering analysis too available in the Ingenuity pathway analysis (IPA) software 
was used to identify novel potential biomarkers. Excel files containing the differentially 
expressed genes (DEGs) obtained from RNA sequencing of tissue samples were uploaded onto 
the IPA platform. The Biomarker filter analysis tool on the IPA platform was then utilized. The 
Biomarker filtering tool by IPA enables for the identification of relevant and novel biomarkers. 
Several filters available on the platform were used, including: 
(i) Species- To indicate species of the organism of interest 
✓ Human 
(ii) Tissues and cell lines- To indicate where the biomarker expressed 
✓ Pancreatic cancer cell lines 
 
(iii) Node types 
✓ All nodes except complexes and groups 
(iv) Diseases- To indicate type of disease 
✓ Cancer 
(v) Biofluids- To indicate where biofluids biomarker can be found 
✓ Blood 
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(vi) Molecules 
✓ All types 
(vii) Biomarker- To indicate novelty of biomarker 
✓ Not a known biomarker 
To further refine biomarker analysis, manual filtering was conducted. Manual filtering 
involved searching through multiple databases including NCBI and the pancreatic cancer 
databases bearing in mind the hallmarks of a good biomarker (see Section 1.2). 
2.2.9 Biomarker (gene) Validation by Real time PCR using RT2 qPCR primer assays 
Procedure 
For this study, the target genes were JUP, COPG and TCIRG1 because they were identified as 
novel potential biomarkers after several Biomarker filtering analyses identified them as novel 
potential biomarkers. MRPL19, a housekeeping gene was used as a control. MRPL19 was 
chosen since its expression remains unchanged during pancreatic cancer (Mohelnikova-
Duchonova et al., 2012). All MIQE guidelines were observed including performing 3 
independent experiments  (Bustin et al., 2009). 
In a 1.5 ml tube the PCR components mix was prepared. The mixture included 12.5 µl RT2 
SYBR Green Mastermix, 1 µl cDNA synthesis reaction, 1µl RT2 qPCR Primer assay and 10.5 
µl RNase-free water for one reaction. The mixture was then thoroughly mixed and transferred 
into a 96-well plate with a pipette. The 96-well plate was covered with an adhesive and 
centrifuged for 1 min at 1000g to remove bubbles. The plate was then placed into the Roche 
LightCycler-480. The cycling condition was set as follows: 95°C for 10 min (1 cycle), 95°C 
for 15 secs (45 cycles) and 60°C for 1 min (45 cycles). At the end of the cycles the Cp values 
were obtained to be used for analysis.  
Data analysis 
Data obtained from the Roche LC-480 were copied into Microsoft excel which was then 
uploaded into the REST software (Pfaffl et al., 2002). The REST software calculates the 
confidence interval, standard error, and the probability of alternate hypothesis that difference 
between sample and control groups is due only to chance. From these calculations, it produces 
the result which includes a box-plot and a statement indicating whether genes were up, 
unchanged, or down regulated. 
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2.2.10 Protein-protein interaction network analysis 
The STRING v9.1 (Franceschini et al., 2013) was used for the protein-protein interaction 
network analysis of the identified novel potential biomarker. STRING enabled us to identify 
known and predicted biological processes and pathways in which components of the network 
are enriched 
2.2.11 Variant filtering analysis 
The Ingenuity Variant Analysis tool (www.qiagenbioinformatics.com/products/ingenuity-
variant-analysis/) was used to identify novel SNP variants. The CLC Genomics work bench 
(which includes the Basis variant detection tool, fixed ploidy variant detection tool, and the 
low frequency variant detection tool) was used for variant calling for all samples (2 normal and 
2 tumour tissues). Variant calling files were then uploaded into the Ingenuity Variant Analysis 
(IVA) platform and analysed. 
Various filters were used to identify gene variants. They include; 
(i) Confidence- This was used to remove suspicious or low quality variants. These 
types of variants are likely to be false positives.  
Only variants that satisfied the following criteria was kept 
✓ Call quality is at least 20 in both case and control  
✓ Variant passed upstream pipeline filtering 
✓ Outside top 5% most exonically variable 100 base windows in healthy 
public genomes. 
(ii) Common variants- This was used to exclude common variants. 
Exclusion criteria included variants that are observed in any of the population with 
the allele frequency of; 
✓ At least 0.5% in 1000 Genomes project (The 1000 Genomes Project 
Consortium, 2015). 
✓ At least 1% in the public complete genomics genome 
✓ At least 0.5% of all NHLBI ESP exomes. 
✓ At least 0.5% in the Allele frequency community. 
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(iii) Predicted deleterious- This filter refers to variants that confer deleterious effects to 
gene function or expression. For this filter, only variants that are experimentally 
observed to be associated with a phenotype were kept: 
✓ Disease-associated per the complete ACMG (American college of genetics 
and genomics) guidelines classification. 
➢ Pathogenic 
➢ Likely pathogenic 
✓ Listed in HGMD® Human gene mutation database) 
✓ Are associated with loss of function of a gene 
➢ Frameshift, inframe indel, start/stop codon change. 
➢ Missense unless predicted tolerated by SIFT or polypen-2 
➢ Splice site loss up to 2 bases into intron or as predicted by 
MaxEntScan. 
(iv) Genetic analysis- This filter was used to keep or exclude variants based on some 
gene analysis criteria. 
✓ Pair matches samples from the same individuals. 
✓ And in both case and control samples, variations that were; Homozygous, 
Heterozygous, Het-ambiguous, Haploinsufficient, Hemizygous and 
Nullizygous 
(v) Cancer driver variants- This filter specifically targets variants and genes associated 
with cancer. 
Only variants found in the following were kept 
✓ cancer-associated mouse knockout phenotypes. 
✓ cancer-associated cellular processes with any directionality 
✓ cancer therapeutic targets 
✓ published cancer literature (Variant and gene level findings) 
✓ known or predicted cancer sub network regulatory sites 
✓ COSMIC at the frequency greater than or equal to 0.01% 
✓ TCGA at a frequency greater than or equal to 0.01% 
(vi) Biological context- This enabled variants that are associated with a specific 
condition (cellular proliferation) to be filtered.  
After these filters were applied, analysis was then performed. 
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Furthermore, manual filtering was performed to identify novel genetic variants. This involved 
a search though several databases as indicated in 2.2.8 
2.2.12 Focused proteomic profiling using Human oncology proteome profiler array 
Brief Description of kit  
The R&D systems Proteome Profiler™ Human Oncology Array kit was used to ascertain 
differential protein expression between normal and tumour samples. It is a sensitive, rapid and 
cost-effective tool. It contains 84 cancer-related proteins on the array membrane. An antibody 
for each protein is present as a spot on the membrane. Each protein spot is duplicated to serve 
as technical replicate. 
Procedure 
Protein expression profiling was carried out using the Proteome Profiler Human XL Oncology 
Array kit. Samples and reagents were prepared per the instructions described by the 
manufacturer. 2 ml of the Array buffer 6 (Block buffer) was pipetted into each well of the 4-
well multi-dish. Each membrane was then placed into separate wells in such a way that the 
numbers on the membranes faced upwards. Membranes were incubated on a rocking platform 
shaker for 1 hr. During this time, 500 µl of the samples were added to 500 µl of Array Buffer 
4 and the final volume adjusted to 1.5 ml with Array Buffer 6. The Array Buffer 6 placed in 
the wells of the multi-dish was removed and the sample mix added and the lid placed on the 
dish. This was then incubated overnight at 4°C on a rocking platform shaker. Each membrane 
was carefully removed from the well using appropriate forceps and placed into separate plastic 
containers with 20 ml of 1X wash buffer for 10 mins on a rocking platform shaker. This wash 
step was repeated 3 times. For each array, 30 µl of detection antibody cocktail was added to 
1.5 ml of 1X Array buffer 4/6 (a mixture of 4 ml Array buffer 4 and 8 ml Array buffer 6). 1.5 
ml of the diluted detection antibody mixture was then added to each well. Each membrane was 
carefully removed from its wash plastic container and placed in the multi-dish containing the 
diluted detection antibody cocktail and covered with the lid. This was then incubated on a 
rocking platform shaker for 1 hr. After incubation, the membrane underwent the washing steps 
described previously. 2 ml of the diluted streptavidin-HRP was added to each well. The 
membrane was then placed in the diluted streptavidin-HRP and incubated for 30 mins on a 
rocking platform shaker. After incubation, the membrane underwent the washing steps 
described previously. The membrane was then placed on a plastic sheet protector. 1 ml of the 
Chemi reagent mix was pipetted onto the membrane, another plastic protector placed on top 
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and the membrane incubated for 1 min. The membrane was using the Bio-Rad Chemi-doc 
system. 
Data analysis 
Differential protein analysis 
The wvision (western vision) QuickSpots software was used to analyse the captured array 
membranes and identify differentially expressed proteins. This software measures the intensity 
of each spot. The average spot intensities of tumour and normal tissue samples was ascertained. 
These intensity values were then exported to Microsoft excel. Standard error and p-values were 
then calculated using Microsoft excel.  
Functional enrichment analysis 
After identification of statistically significant (p< 0.05) differentially expressed proteins, the 
REACTOME (Croft et al., 2011) software was used to classify pathways in which they were 
enriched. Only pathways and biological processes with P < 0.05 were considered.  
2.2.13 Biomarker filtering analysis 
Biomarker filtering analysis was performed as described in 2.2.8 
2.2.14 Protein-protein interaction network analysis 
After identification of potential protein biomarkers protein-protein interaction network analysis 
was done as described in 2.2.10. 
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CHAPTER 3- RESULTS 
3.1 Summary of results  
Using the Human Cancer PathwayFinder RT2 Profiler PCR arrays differential gene expression 
(DEGs) profiles of pancreatic tissue samples-obtained from PDAC patients- and the pancreatic 
cancer cell line, MIA PaCa-2, was shown. Pathway analysis was then performed to compare 
DEGs identified in tissue samples to those observed in the pancreatic cancer cell line. 
Upregulated genes in tumour tissues were observed to be uniquely enriched in pathways 
associated with necrosis. After biomarker analysis, RT2 Profiler PCR arrays did not identify 
any novel potential biomarker thus RNA sequencing was performed.  
Differential gene analysis of RNA sequencing data revealed 4911 upregulated and 5 
downregulated genes. I performed gene ontology analysis and observed that the upregulated 
genes were enriched in biological processes associated with nuclear transport. Also, these 
genes enriched signalling pathways included the insulin/IGF/MAPK cascade, integrin 
signalling pathway and Ras signalling pathway. Gene network analysis showed an intricate 
interaction network of most upregulated genes. Furthermore, downregulated genes were 
observed to be enriched in several processes including metabolism, embryonic patterning, 
glycosylation, and protein transport. 
Using the IPA biomarker tool, 3 novel potential biomarkers- JUP, COPG and TCIRG1 were 
identified. To further validate these biomarkers, real time PCR was done and the upregulation 
of JUP across additional tissue samples confirmed. Protein-protein interaction (PPI) network 
analysis showed that JUP and functional interactors were enriched in pathways associated with 
cancer. 
In this study, 87 genetic variants associated with PDAC which were then filtered to identify 
those predicted to result in loss of gene function and are only present in tumour samples. This 
filtering process identified 6 variants present in 4 genes-  SPARC, ZFHX3, COLIA1, and TGM2. 
Furthermore, 18 significantly (p<0.05) upregulated proteins in tumour tissue samples were 
identified. These proteins are observed to be enriched in pathways associated with signal 
transduction and the immune system. ANGPTL4 and p27kip1- were further identified as novel 
potential biomarkers. Also, ANGPTL4 PPI network analysis identified lipid metabolism and 
PPAR signalling enriched biological process and pathway respectively. Similarly, p27/kip1 
PPI network analysis identified cell cycle as the most enriched biological process. 
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3.2 Gene expression profile in tumours and MIA PaCa-2 
MIA PaCa-2 is a widely used pancreatic cancer cell line obtained from a Caucasian male (as 
described in 2.2.3) and tissue samples used in this study were obtained from black South 
African patients. As gene expression profiles can differ between biological samples and 
population, I have compared the differential expressed genes in pancreatic tumours to those in 
the cell line. Two pancreatic tumour tissues were obtained from different PDAC patients 
(patient 1 and 2) and normal tissue obtained from patient 1. RNA obtained from biological 
samples were converted to cDNA and pipetted into the human cancer PathwayFinder RT2 
Profiler array. The array was then placed in the Roche lightcycler-480 and analysed. Cp values 
were generated and further analysed. Cp values of both tumour samples were averaged and 
then compared to those of the normal tissue (this was referred to as Group 1). Similarly, Cp 
values from MIA PaCa-2 were generated and compared to those from the normal tissue 
(referred to as Group 2). 
All samples and arrays used passed data quality control tests (Figure A1 in appendix). Amongst 
the reference genes in the array, B2M was observed to be the most stable across all samples 
and was therefore used for normalization (Figure A2 in appendix).  
Visualization of gene expression profiles 
The QIAGEN RT2 Profiler PCR analysis software was used to generate heat maps to help 
visualize differential gene expression profile for both Group 1 and Group 2 (Figures 3.1). 
Visual inspection of heatmaps for Groups 1 and 2 showed differences in gene expression 
between both groups. Differential gene expression analysis for Group 1 showed the 
upregulation of 20 genes and downregulation of 20 genes. For Group 2, 32 genes were 
upregulated while 41 genes down regulated.  
 
 
33 
 
 
Figure 3.1: Heat map of fold changes observed in Group 1 (a) and Group 2 (b) for the various genes 
within the array. Colour bar indicating expression levels is also shown. Fold regulation of genes can be 
observed as colours indicated in the colour bar. Negative values indicate downregulation and positive 
values, upregulation. Individual fold change values are shown in figure A3 in the appendix section.  
 
Pathway analysis of Group 1 and Group 2 DEGs 
Heatmap representations showed variances in differential gene expression between Group 1 
and 2, I then sought to identify dysregulated genes unique in both groups. Unique in the sense 
that they were dysregulated in Group 1 but not in Group 2 and vice versa. In Group 1, 10 genes 
were uniquely upregulated and 6 downregulated. In Group 2, 23 were uniquely upregulated 
and 25 downregulated (Table A6 in appendix section).  
To identify pathways in which uniquely DEGs for Group 1 and 2 were enriched in, pathway 
analysis using REACTOME software was utilized. Downregulated genes unique to each group 
were input separately into the system and an output of a diagram and table showing enriched 
pathways were generated (Figure 3.2, Table 3.1). This process was replicated for upregulated 
genes (Figure 3.3, Table 3.2)  
 
 
 
 
34 
 
 
 
Figure 3.2: Diagrammatic representation of enriched pathways of downregulated genes unique to Group 
1 (a) and Group 2 (b). Orange coloured lines indicate enriched pathways. Group 1 is normal tissue vs 
tumour tissue and Group 2 is normal tissue vs MIA PaCa-2 cell line. Generated from REACTOME 
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Table 3.1: Top 10 pathways enriched in downregulated genes unique to Group 1 and Group 2 
Group 1 (tumour vs normal tissue) Group 2 (MIA PaCa-2 vs normal tissue) 
Pathway p-value Pathway p-value 
Formation of cornified 
envelope 
3.733E-5 VEGF ligand-receptor 
interactions 
3.01E-6 
VEGF ligand-receptor 
interactions 
6.71E-5 VEGF binds to 
VEGFR leading to 
receptor dimerization 
3.01E-6 
VEGF binds to 
VEGFR leading to 
receptor dimerization 
6.71E-5 Tie2 signalling 6.05E-5 
Keratinization 2.71E-4 Neurophilin interactors 
with VEGF & VEGFR 
8.84E-5 
Developmental 
biology 
5.33E-3 Oncogene induced 
senescence 
3.75E-4 
Formation of 
apoptosome 
7.44E-3 Cellular senescence 5.12E-4 
SMAC-mediated 
apoptotic response 
7.44E-3 Signalling by VEGF 1.69E-3 
SMAC-mediated 
dissociation of IAP: 
caspase complexes  
7.44E-3 TBS3 regulates 
transcription of death 
receptors and ligands 
1.74E-3 
SMAC binds to IAPs 7.44E-3 Regulation of insulin-
like growth factor 
transport uptake by 
insulin-like growth 
factor binding proteins 
2.57E-3 
Cell junction 
organization 
8.23E-3 Developmental 
biology 
4.38E-3 
 
Pathways enriched by downregulated genes in both groups can be observed in figure 3.2. 
Amongst the top 10 most enriched pathways, VEGF binding and developmental biology were 
common to both groups. The formation of cornified envelope was observed to be the pathway 
in which Group 1 downregulated genes were most significantly enriched (p = 3.733 E-5). 
VEGF ligand-receptor interactions followed by VEGF binds to VEGFR leading to receptor 
dimerization (p values of 6.71E-5) (Table 3.1). Group 2 downregulated genes were mostly 
enriched in VEGF ligand-receptor interactions followed by VEGF binds to VEGFR leading to 
receptor dimerization both with a p values of 3.01E-6. Group 1 was observed to have some 
unique pathways including; formation of cornified envelope, keratinization, formation of 
apoptosome, SMAC-mediated apoptotic response and cell junction organization. In 
comparison, Group 2 also had some unique significantly downregulated pathways including; 
cellular senescence, oncogene induced senescence and regulation of insulin-like growth factor 
transport uptake by insulin-like growth factor binding proteins. 
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Figure 3.3: Diagrammatic representation of enriched pathways of upregulated genes unique to Group 1 
(a) and Group 2 (b). Orange coloured lines indicate enriched pathways. Group 1 is normal tissue vs 
tumour tissue and Group 2 is normal tissue vs MIA PaCa-2 cell line. Generated by REACTOME. 
 
 
 
 
 
 
a 
b 
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Table 3.2: Top 10 pathways enriched in upregulated genes unique to Group 1 and Group 2. 
Group 1 (Tumour vs normal tissue) Group 2 (MIA PaCa-2 vs normal tissue) 
Pathway p-value Pathway p-value 
Unwinding of DNA 3.69E-6 Ub-specific processing 
proteases 
6.59E-6 
Regulation of 
necroptotic cell death 
1.69E-5 Unwinding of DNA 1.08E-5 
RIPK1-mediated 
regulated necrosis 
4.1E-5 XAV939 inhibits 
tankyrase stabilizing 
AXIN 
5.22E-5 
Regulated necrosis 4.1E-5 Deubiquitination 5.34E-5 
Activation of pre-
replicative complex 
8.82E-5 G1/S transition 4.88E-2 
DNA strand 
elongation 
1.12E-4 TCA & respiratory 
electron transport 
6.32E-3 
Activation of ATR in 
response to replication 
stress 
1.21E-4 S phase 7.13E-3 
Oncogene induced 
senescence 
1.4E-4 Mitotic G1-G1/S 7.13E-3 
Pyruvate metabolism 1.97E-4 Activation of the pre-
replicative complex 
9.11E-3 
Cellular response to 
stress 
2.15E-4 Cell cycle 9.33E-3 
 
Upregulated genes for both groups were enriched in pathways associated with metabolism and 
signal transduction (Figure 3.3). The top 10 enriched pathways for both groups were observed 
to have one pathway in common; Unwinding of DNA. However, Group 1 genes are also 
observed to be enriched in pathways involved in programmed cell death. This enrichment was 
identified to be in pathways involved in necrosis (Table 3.2). Unwinding of DNA is the most 
enriched pathway in Group 1 genes (p value=3.69E-6), while Ub-specific processing proteases 
is for Group 2. Pathways enriched by Group 2 genes were mostly associated with cell cycle 
progression. These pathways include; mitotic G1-G1/S, S phase, G1/S transition, activation of 
pre-replicative complex and cell cycle. On the other hand, Group 1 genes were mostly 
associated with necrosis and response to stress pathways. These pathways include; regulated 
necrosis, regulation of necroptotic cell death, activation of ATR in response to replication 
stress, and cellular response to stress. 
Biomarker filtering analysis 
To identify potential novel biomarkers, biomarker analysis was conducted. This analysis 
included using the Ingenuity pathway analysis tool and manual analysis. Differentially 
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expressed genes identified from both Groups 1 and 2 were used in this analysis. As no potential 
novel biomarkers were identified from the DEGs; thus, RNA sequencing was conducted. 
3.3 Differential gene expression using RNA sequencing  
RNA sequencing was conducted to enable gene expression analysis of a much larger pool of 
genes. Four samples from 2 patients were used and were those previously used for the RT2 
profiler PCR array. From each patient one normal and one tumour sample was utilized. Both 
tumour samples were obtained from stage 1 PDAC patients. Patient 1 was a 62-year-old female 
and patient 2 was a 68-year-old male. After RNA extraction samples were sent to Inqaba-biotec 
for sequencing and differential gene expression analysis. Each patients tumour samples were 
compared to their corresponding normal tissues. That is, for patient 1, tumour (T1) was 
compared to normal tissue (N1) and for patient 2, tumour (T2) was compared to normal tissues 
(N2). 
Differential gene expression analysis using the CLC genomics workbench identified 8032 
upregulated in the tumour from patient 1 while 7456 were overexpressed in that of patient 2. 
Amongst the upregulated genes, 4911 were observed to be upregulated in both patients. 
Furthermore, 54 and 558 genes were identified to be downregulated in patient 1 and 2 
respectively.  Amongst the downregulated genes, only 5 were common to both (Figure 3.4). 
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Figure 3.4: Venn diagrams showing differentially expressed genes. (a) Genes upregulated in sample 
sets. 4911 genes are common to both sets. (b) Genes downregulated in sample sets. 5 genes common to 
both sets. 
 
To visualize differential gene expression in both patients the MORPHEUS software was used. 
Differentially expressed genes for both patients were uploaded into the software and heatmap 
generated (Figure 3.5). Expected variations between gene expression patterns of both patients 
were observed from the heatmap (see Section 1.2.1). 
 
4911 
5 
a 
b 
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Figure 3.5: Heatmap showing differentially expressed genes for both sample sets. N1vsT1 indicates 
normal vs tumour from patient 1 while N2vsT2 indicates normal vs tumour from patient 2. Blue colour 
represents down regulation and Red indicates upregulation. Heatmap was generated from MORPHEUS 
software. 
 
Functional enrichment analysis of upregulated genes 
To group upregulated genes per roles they play, functional enrichment analysis was performed. 
The 4911 upregulated genes common to both sample sets were uploaded into the PANTHER 
software and analysed. The PANTHER software was used to analyse the pathways, biological 
processes, molecular functions, and protein classes enriched by the upregulated genes.  
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The Insulin/IGF pathway-mitogen activated protein kinase/MAP kinase cascade is observed to 
be the most enriched pathway. This pathway had a fold enrichment of 2.62 and p-value of 
2.19E-02. It is followed by the integrin signalling pathway and Ras signalling pathway (p-
values 9.65E-15 and 1.10E-03 respectively). Furthermore, the PDGF and EGFR signalling 
pathway were also observed to be enriched. Examination of the top 10 list indicate that our 
upregulated genes were mostly enriched in pathways involved in several signalling pathways 
(Table 3.3).  
Table 3.3: Showing top 10 pathways enriched by genes upregulated in tumour tissues.  
Pathways Homo 
sapiens 
(Reference) 
Client 
input 
Expected Fold 
enrichment 
p-value 
Insulin/IGF pathway-
mitogen activated protein 
kinase/MAP kinase 
cascade 
33 20 7.64 2.62 2.19E-02 
Integrin signalling 
pathway 
192 110 44.45 2.47 9.65E-15 
Ras pathway 76 39 17.59 2.22 1.10E-03 
PDGF signalling pathway 149 73 34.49 2.12 1.06E-06 
EGF receptor signalling 
pathway 
139 67 32.18 2.08 7.72E-06 
Angiogenesis 176 83 40.74 2.04 5.58E-07 
CCKR signalling map 173 81 40.05 2,02 1.16E-06 
VEGF signalling 
pathway 
72 33 16.67 1.98 4.11E-02 
B cell activation 72 33 16.67 1.98 4.11E-02 
Gonadotropin-replacing 
hormone receptor 
pathway 
235 106 54.40 1.95 4.70E-08 
 
The most enriched biological process observed was nuclear transport (p =3.8E-02) (Table 3.4). 
An over representation of upregulated genes in nuclear transport was observed with a fold 
enrichment of 1.82 is shown. This is followed by nuclear localization (p = 1.17E-06). 
 
. 
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Table 3.4: Showing top biological processes enriched by genes upregulated in tumour tissues.  
GO ID Biological 
process 
Homo 
sapiens 
(Reference) 
Client 
input 
Expected Fold 
enrichment 
p-value 
GO:0051169 Nuclear 
transport 
107 45 24.77 1.82 3.80E-
02 
GO:0051179 Nuclear 
localization 
2144 622 496.33 1.25 1.17E-
06 
GO:0000398 mRNA splicing, 
via spliceosome 
174 70 40.28 1.74 3.03E-
03 
GO:0006397 mRNA 
processing 
242 91 56.02 1.62 2.31E-
03 
GO:0006139 Nucleobase-
containing 
compound 
metabolic 
process 
3160 835 731.54 1.14 5.91E-
03 
GO:0044238 Primary 
metabolic 
process 
5773 1536 1336.44 1.15 3.42E-
08 
GO:0008152 Metabolic 
process 
6817 1837 1578.13 1.16 6.48E-
13 
GO:0000375 RNA splicing 
via transcription 
reaction 
134 53 31.02 1.71 4.71E-
02 
GO:0006325 Chromatin 
organization 
263 93 60.88 1.53 1.69E-
02 
 
The most enriched molecular functions of the upregulated genes were investigated and it was 
determined that most genes were involved in Rac GTPase binding. Rac GTPase had a fold 
enrichment of 3.35. It was followed by Rho GTPase binding and Ras GTPase binding. Most 
of the upregulated genes were observed to function in various types of binding. Table A7 in 
the appendix section shows the top 10 most enriched molecular functions.  
Cellular location of dysregulated genes can be crucial in elucidating the biology of PDAC. The 
cellular components enriched by the upregulated genes were investigated. It was observed that 
the ribososme is the most enriched cellular component with a p-value of 3.01E-04 and fold 
enrichment of 1.96. Furthermore, the genes were also enriched in ribonucleoprotein and 
macromolecular complexes. These complexes come in 2nd and 3rd in the list with fold 
enrichments of 1.42 and 1.23 respectively. A closer look at Table A8 (appendix section) shows 
that many the upregulated genes were located intracellularly.  
Grouping of genes-of-interest per protein class help in further understanding their role in 
PDAC. Protein classes were observed and nucleic acid binding identified as the most enriched 
with a p-value of 5.83E-10 and fold enrichment of 1.29. Table A9 (Appendix) shows that 2706 
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of the upregulated genes are enriched in the protein class involved with nucleic acid binding. 
Enzyme modulator and transferase follow (p-values 8.68E-12 and 1.35E-03 respectively). 
To investigate the transcription factors and clinical phenotypes enriched by the upregulated 
genes the FunRich software was used. The 4911 upregulated genes were uploaded onto the 
software and then analysed. Figure A4 (Appendix) shows the top 6 transcription factors 
enriched by the upregulated genes. SP1(Specificity protein 1) shown to be the most enriched 
with 58.8% of the genes. SP4 followed with 37.4 % of genes and EGR1 with 28.3%. Members 
of the SP family- SP1 and SP4 are observed to play a role in the transcription of the upregulated 
genes. The KLF7, YY1 and GABPA are also significantly enriched. All 6 transcription factors 
are observed to have p-values less than 0.001 except for YY1. 
Furthermore, more than 72% of the upregulated genes were observed to be expressed in the 
skin. The joint laxity and nerve conduction velocity were also enriched with 3.9% and 1.1% 
respectively of the upregulated genes (Figure A5). 
Gene network analysis of upregulated genes 
To examine the inter-connectedness of upregulated genes, gene network analysis was 
performed using FunRich. Majority of upregulated genes were observed to be part of an 
intricate network (Figure 3.6) with exception to just a minute number (right corner of Figure 
3.6). A close look at figure 3.7 show that most of these genes were linked together by diverse 
interactions. These interactions might be linked to similar biological processes or pathways.  
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Figure 3.6: Diagram showing intricate gene network of upregulated genes. Red nodes indicate 
upregulated genes. Red edges (lines) indicate interactions. A magnified section of the gene network 
shows a clearer interaction of the genes. Generated from FunRich. 
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Functional enrichment of downregulated genes 
To understand the roles played by the downregulated genes, functional enrichment analysis 
was performed. Only 5 common genes were downregulated in both patients, they included: 
CXXC4, GALNT1, HS3ST4, SLC15A4 and TSPAN7. The 5 genes were uploaded onto the 
DAVID software and analysed. Attempt to group downregulated genes per molecular 
functions, biological processes, and pathways in which they are involved did not yield any 
result. Downregulated genes were then analysed individually. A comprehensive table 
highlighting diverse roles and properties of these genes can be observed in Table A10, 
however, they are summarized below: 
CXXC4 was observed to be enriched in biological processes involved in embryonic patterning, 
axis formation and negative regulation of signal transduction. It is mostly enriched in 
cytoplasmic and membrane bound vesicles. CXXC4 functions mostly in DNA and ion binding. 
Its most enriched pathway is the Wnt signalling pathway. 
GALNT1 was mostly enriched in biological processes involving glycosylation and can be found 
in the membrane, Golgi apparatus and extracellular matrix. GALNT1 functions in 
acetylgalactosaminyltransferase activity, sugar, and ion binding. Its most enriched pathway is O-glycan 
biosynthesis. 
HS3ST4 was identified to be involved in proteoglycan and glycoprotein metabolic processes. 
Just like GALNT1, it is found to be localized in the membrane, Golgi apparatus and 
extracellular matrix. HS3ST4 belongs to the protein class of sulfotransferases and therefore 
functions as such.  
SLC15A4 was mostly enriched in biological processes involving protein transport and 
localization. It is found mostly in the membrane, vacuole, and lysosome where it functions in 
symporter and transporter activities. 
TSPAN7 belongs to the protein class of tetraspanins and is mostly localized in the plasma 
membrane. It is involved in several biological processes including; protein amino acid 
glycosylation, glycoprotein metabolic process, and glycoprotein biosynthetic process. 
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Gene network analysis of downregulated genes 
To identify genes interacting with the downregulating genes, gene network analysis was 
performed using GeneMania. It was observed that altogether the five downregulated genes had 
20 interacting partners (Figure 3.7).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Gene network of downregulated genes including interactions. Nodes on the left indicate 
downregulated genes. On the right are interacting partners of downregulated genes. The bigger the sizes 
of nodes on the left, the greater the certainty of interaction. Key to colour edges can be seen at the 
bottom left of the diagram. 
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To further elucidate the roles which these genes play in the network, pathway analysis was 
performed in REACTOME using the downregulated genes and their interacting partners as 
input. Table 3.5 shows the top 5 most downregulated pathways. Downregulated genes were 
observed to be involved in the Wnt signalling and membrane trafficking pathways. NCAPH 
observed in figure 3.7 as the most prominent interacting partner seem to be absent in the top 
enriched pathways 
Table 3.5: Showing pathways enriched by downregulated gene network components 
Pathways Genes involved p-value 
Proton/oligopeptide co-
transportation 
SLC15A1, SLC15A2, 
SLC15A4 
1.21E-07 
Wnt signalling DVL2, DVL3, CXXC4 2.36E-07 
Intra-golgi and retrograde 
Golgi-to-ER traffic 
KIFC, GALNT1, KIF5A, 
MANIA1 
1.12E-03 
Membrane trafficking SEC23B, KIF5C, GALNT1, 
KIF5A, DVL2, MANIA1 
2.82E-03 
MHC Class II antigen 
presentation 
SEC23B, KIF5C, KIF5A 3.87E-03 
 
3.4 Gene biomarker discovery and validation 
For identification of novel potential biomarkers, the 4911 upregulated genes common to 
patients 1 and 2 were used for biomarker filtering analysis. After filtering with the IPA 
biomarker analysis software, 101 genes were identified as potential biomarkers of pancreatic 
cancer. The IPA analysis tool filtered genes based on several criteria describe in section 2.2.8 
Additional manual biomarker filtering identified 3 novel potential biomarkers – JUP, COPG, 
and TCIRG1. As mentioned in 2.2.8 manual filtering involved a search through several 
databases to ascertain the novelty of genes as potential biomarkers. Furthermore, the 
characteristics of a good biomarker (see section 1.2) were taken into consideration in selecting 
these biomarkers. 
An additional ten samples (5 tumour and 5 normal) were obtained from 6 different patients. 
These patients’ samples were not included in those used for RNA sequencing. All samples 
were obtained from stage I PDAC patients. Real-time PCR was performed and Cp values 
obtained. Analysis using the REST software analysed the Cp values of the 3 genes and 
normalized to the reference gene- MRPL19.  
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Table 3.6 and Figure 3.8 show JUP was UP-regulated in tumour (in comparison to normal 
group); p(H1) of 0.012. The expression of COPG in tumour was not different to normal tissues 
(p(H1) =0.703). TCIRG1 was also unchanged in normal and tissue samples ( P(H1) of 0.597). 
Although the expression of JUP was identified as upregulated in tumour tissues it is observed 
to have a wide 95% confidence interval (CI) of 1.25 - 1,856.39. Future validation studies with 
the use of a lot more samples would be appropriate to correct the large CI. 
  
Table 3.6: Results of Real-time PCR performed on potential novel biomarkers. 
Legend: 
p(H1) - Probability of alternate hypothesis that difference between tumour and normal groups is due 
only to chance. 
TRG - Target 
REF – Reference 
Gene Type Reaction Efficiency Expression Std. Error 95% C.I. P(H1) Result 
JUP TRG 1.0 33.778 3.925 - 407.131 1.246 - 1,856.393 0.012 UP 
MRPL19 REF 1.0 1.000         
COPG1 TRG 1.0 1.887 0.132 - 43.829 0.006 - 96.567 0.703   
TCIRG1 TRG 1.0 2.378 0.052 - 77.719 0.003 - 348.572 0.597   
 
 
 
Figure 3.8: Box plot of expression ratio of JUP, COPG, and TCIRG1 in tumours (n=6) compared to 
corresponding normal tissues (n=6). Boxes represents the interquartile range, or the middle 50% of 
observations. The dotted line represents the median gene expression. Whiskers represent the minimum 
and maximum observations. Boxplot generated from REST software. 
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Functional enrichment analysis of the JUP PPI network  
The preliminary validation of JUP as a novel potential biomarker, prompted the analysis of PPI 
network it is involved in. Using the STRING software tool, the PPI network of JUP was 
observed (Figure 3.9). All functional interactors had a confidence score greater than 0.9 (Table 
3.7). The STRING software tool uses confidence score to describe the degree of certainty of 
interaction between molecules. Confidence score rages from 0-1, thus, any score of >0.9 is 
considered good. Amongst these partners, CTNNA1 is shown to be with the highest confidence 
score of 0.993. TCFL7 and CDH2 follow with confidence scores of 0.991 and 0.987 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Protein-protein interaction network of JUP. The network has a PPI enrichment p- value of 
1.38E-05. Edges represent various types of interactions as indicated above. Generated from STRING. 
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Table 3.7: Predicted functional partners of JUP PPI network 
Protein 
symbol 
Protein name Confidence 
Score 
CTNNA1 Catenin alpha 1 0.993 
TCF7L2 Transcription factor 7-like 2 0.991 
CDH2 Cadherin 2, type 1, N-Cadherin 0.987 
CDH1 Cadherin 1, type 1, E-Cadherin 0.986 
DSC1 Desmocollin 1 0.949 
AXIN1 Axin 1 0.945 
TCF7 Transcription factor 7 0.943 
DSC2 Desmocollin 2 0.941 
APC2 Adenomatosis polyposis coli 2 0.936 
CDH5 Cadherin 5 0.935 
 
To further understand the roles played by JUP and its interaction partners, functional 
enrichment analysis of the PPI network was conducted. The biological processes, molecular 
functions and pathways enriched by the network of proteins were observed.  
Cellular response to indole-3-methanol was shown to be the most enriched biological process 
in the JUP PPI network with 3 genes being involved in the process and a false discovery rate 
(FDR) of 7.97E-06 (Table 3.8). Cell-cell adhesion followed with the most number of genes-7- 
involved in this process and a false discovery rate of 1.044E-05. 
Table 3.8: Top 5 biological processes enriched in JUP PPI network 
Pathway ID Pathway description Count in gene set False discovery rate 
GO: 0071681 Cellular response to 
indole-3-methanol 
3 7.97E-06 
GO:0098609 Cell-cell adhesion 7 1.044E-05 
GO:0007156 Homophilic cell 
adhesion via plasma 
membrane adhesion 
molecules 
5 2.15E-05 
GO:0016337 Single organismal cell-
cell adhesion 
6 5.9E-05 
GO:0046822 Regulation of 
nucleocytoplasmic 
transport 
5 5.9E-05 
 
Furthermore, genes in the JUP PPI network are also implicated in endometrial (FDR= 2.05E-
11) and colorectal cancers (FDR= 8.42E-07). Seven of the genes within the network are also 
shown to be associated with pathways in cancer (FDR= 4.82E-09). 
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Table 3.9: Top 5 pathways enriched in JUP PPI network 
Kegg Pathway ID Pathway 
description 
Count in gene set False discovery 
rate 
05213 Endometrial cancer 6 2.05E-11 
05412 Arrhythmogenic 
right ventricular 
cardiomyopathy 
6 1.09E-10 
04390 Hippo signalling 
pathway 
6 4.82E-09 
05200 Pathways in cancer 7 4.82E-09 
05210 Colorectal cancer 4 8.42E-07 
 
Further analysis of the JUP PPI network functions showed their involvement in different types 
of binding (Table A11). Beta-catenin binding was the most enriched with 8 out of 11 genes 
involved and a false discovery rate of 7.87E-16. 10 genes in the JUP PPI network are observed 
to function in protein binding. 
 
3.5 Discovering genetic variants involved in PDAC 
Variant analysis is crucial for elucidating the progression of PDAC as one of the hallmarks of 
cancer is mutation in certain crucial genes. To identify genetic variants, we used the Ingenuity 
Variant analysis tool. Using the CLC genomics workbench, variant calling was performed from 
the RNA sequencing data. Each of the 4 samples had a VCF (Variant calling file) which was 
loaded into the IVA software. Stringent variant filtering analysis was then undertaken (see 
2.2.12). 
Figure 3.10 shows a schematic flowchart of the variant filtering done using the Ingenuity 
variant analysis software. Prior to commencement of filtering, there were 3453 variants in 359 
genes observed in our samples. Every filter applied decreased the number of variants. The first 
filter applied was the confidence filter which reduced the variants to 3268. Five more filters- 
common variants, predicted deleterious, genetic variants, cancer driver variants and biological 
context- were also applied. This extensive filtering processes identified 87 variants present in 
30 genes. Filtering parameters have been explained in section 2.2.12 
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Figure 3.10: Schematic diagram showing the number of resulting variants and genes as each filter is 
applied. 3453 variants and 359 genes were reduced to 87 and 30 respectively after 6 filters. 
 
Functional enrichment analysis of variants 
To further elucidate the roles these genetic variants play in the progression of PDAC, functional 
enrichment analysis was performed. This analysis was performed using the Ingenuity variant 
analysis software and it included; grouping genetic variants based on disease phenotype, 
biological processes, and enriched pathways. 
Filtering 
parameters 
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Several crucial pathways were affected by the observed genetic variants (see in Appendix for 
pie chart). The top 10 pathways in which the variants are enriched are shown in (Table 3.10). 
The Aryl hydrocarbon signaling pathway was the most enriched (p=1.081E-6) with a total 
number of 6 variants. Followed by the protein ubiquitination pathway with 12 variants 
(p=2.859E-06). 
Table 3.10: Top 10 pathways enriched in the observed genetic variants. 
Pathways Number of genes Number of variants P-value 
Aryl hydrocarbon 
receptor signalling 
4 6 1.081E-06 
Protein ubiquitination 
pathway 
4 12 2.859E-06 
Phagosome maturation 3 4 1.545E-05 
Small cell lung cancer 
signalling 
3 6 1.678E-05 
Antigen presentation 
pathway 
2 2 1.200E-04 
cdc 42 signalling 3 3 1.746E-04 
Neuroprotective role of 
THOP1 in Alzheimer’s 
disease 
2 2 1.816E-04 
Xenobiotic metabolism 
signalling 
3 3 2.046E-04 
Dendritic cell 
maturation 
3 6 2.227E-04 
Huntington’s disease 
signalling 
3 3 2.264E-04 
 
Furthermore, the identified variants were enriched in several biological processes (see in 
appendix section). Genetic variants would impact crucially on these processes. The top 10 
biological processes enriched by the 87 variants were also observed (Table 3.11). Interestingly, 
apoptosis was identified as the most enriched (p= 1.307E-25) with 69 variants associated in the 
biological process. Cell death followed with 71 variants enriched (p=1.702E-24). Other 
enriched biological processes include; necrosis, developmental biology, and the proliferation 
of cells.  
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Table 3.11: Top 10 biological processes enriched in the observed genetic variants. 
Biological processes Number of genes Number of variants P-value 
Apoptosis 26 69 1.307E-25 
Cell death 27 71 1.702E-24 
Cell death and survival 27 71 8.987E-24 
Necrosis 24 50 1.356E-21 
Proliferation of cells 25 66 3.538E-21 
Molecular biology 26 70 5.182E-21 
Disorder of 
gentinourinary system 
28 83 6.579E-21 
Cell biology 30 87 7.131E-21 
Developmental biology 25 68 2.695E-20 
Immunology 27 78 3.484E-20 
 
The diseases in which our 87 variants were enriched were investigated and 30 diseases 
identified (see Appendix section). The top 10 diseases in which the variants are known to be 
enriched are shown in (Table 3.12). Gastrointestinal tract cancer was observed to be the top 
disease with 86 variants being enriched (p=1.375E-23). Diseases of the pancreas was also 
observed to be amongst the top 10 most enriched diseases with the involvement of 71 variants 
(p= 2.130E-22). 
Table 3.12: Top 10 diseases enriched in the observed variants. 
Diseases Number of genes Number of variants p-value 
Gastrointestinal tract 
cancer 
29 86 1.375E-23 
Gastrointestinal tract 
cancer & tumours 
29 86 2.042E-23 
Abnormalities of 
abdominal organ 
29 86 9.574E-23 
Gastrointestinal 
disturbance 
29 86 1.133E-22 
Reproductive system 
disease 
28 83 1.365E-22 
Diseases of the 
gastrointestinal tract 
29 86 1.380E-22 
Diseases of the 
pancreas 
24 71 2.130E-22 
Adenocarcinoma 29 86 3.622E-22 
Endocrine system 
disorder 
27 79 8.876E-22 
Digestive system 
cancer 
29 86 1.169E-21 
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Novel variant discovery 
The 87 variants were further filtered manually to identify novel ones. The manual filtering 
process involved; the selection of genetic variants present in both tumour samples only, those 
resulting in loss of gene function and that have not been previously reported on in any 
publication. It is important to note that it was the IVA software tool that predicted these 
variations to result in loss of gene function. This manual filtering led to the identification of 6 
variants present in 4 genes- SPARC, ZFHX3, COL1A1 and TGM2. Table 3.13 shows the 
variants, region, and type of variations, including their impact on translation. 
The COL1A1 contains 3 variants leading to splice site loss. A deletion in the exonic region of 
ZFH3 and SPARC results in frameshift. Furthermore, a single nucleotide variation at the splice 
site of TGM2 results in a splice site loss. 
Table 3.13: Showing manually filtered variants resulting in loss of gene function. 
Gene symbol Chromosome Position Gene 
region 
Type of 
variation 
Translation 
impact 
SPARC 5 151043159 Exonic Insertion Frameshift 
ZFHX3 16 72821648 Exonic Deletion Frameshift 
COL1A1 17 48263999 Splice site SNV Splice site loss 
COL1A1 17 48265999 Splice site Insertion Splice site loss 
COL1A1 17 48268176 Splice site SNV Splice site loss 
TGM2 20 36784493 Intronic, 
splice site 
SN Splice site loss 
 
3.6 Differential protein expression in occurring in pancreatic tumours  
To identify differentially expressed proteins occurring during PDAC, human oncology 
proteome profiler arrays were used. As described in section 2.2.13, these arrays are highly 
sensitive antibody arrays with in-built technical replicates. Three patients, samples were used. 
From each patient, one normal and one tumour tissue was obtained. All samples were obtained 
from stage I PDAC patients. Total protein was extracted from tissues and array experiment 
conducted. The arrays were viewed in a Chemi Doc instrument and images captured (Figure 
3.11).   
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Figure 3.11: Arrays showing protein expression profile for normal and tumour tissues from 3 patients. 
Each paired spot represents a protein. As spot intensity increases protein expression is said to increase. 
Paired spots at the top left, bottom left and top right (all shown by red circles on patient 1 normal tissue) 
serve as positive control while bottom right (blue circle) serve as negative control. These positive and 
negative controls are present in same position (indicated in patient 1 normal) in all arrays.  
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Significantly differentially expressed proteins 
Captured images were further analysed using the wvision Quickspot software. The wvision 
Quickspot software provided spot intensity values for each protein. These values were then 
exported to Microsoft Excel. The averages and standard error values of each protein in both 
normal and tumour tissues were calculated. The spot intensity values for each protein in the 
tumour were then compare to those of normal counterparts. Only differentially expressed genes 
with p <0.05 were considered. No significantly downregulated proteins were observed in 
tumour samples compared to normal tissues. However, 19 significantly upregulated proteins 
(with p-value >0.05) were observed in tumour tissues compared to normal tissues (Table 3.14). 
These proteins were further plotted on a bar chart. Nectin -4 was identified to be the most 
significantly upregulated with a p-value of 4.852E-03. This was followed by P27/Kip1 
(CDKN1B) and MUC-1 with p-values 5.966E-03 and 8.420E-03. The spot intensity for CapG 
is seen to be the highest with about 40000 (Figure 3.12), however, when compared to its normal 
samples it places 4th on the list of significantly upregulated proteins. 
Table 3.14: Significantly upregulated proteins with their p-values 
Protein p-value 
Nectin-4 4.852E-03 
P27/Kip 1 
(CDKN1B) 
5.966E-03 
MUC-1 8.420E-03 
CapG 1.021E-02 
Cathepsin D 1.229E-02 
ERalpha/NR3A1 1.575E-02 
Cathepsin S 1.702E-02 
ErbB3/Her3 1.741E-02 
Hif-1 alpha 1.820E-02 
Endoglin/NR3A1 1.864E-02 
EGFR/ErbB1 2.099E-02 
Galectin-3 2.378E-02 
Cathepsin B 2.712E-02 
ENPP-2/Autotaxin 2.829E-02 
SPARC 3.125E-02 
Angiopoietin-like 4 3.958E-02 
CEACAM-5 4.112E-02 
Osteopontin (OPN) 4.296E-02 
DLL1 4.873E-02 
 
 
58 
 
 
 
Figure 3.12: Bar charts of upregulated proteins. Proteins in chart (a) have maximum spot intensity of 
40000 while those in chart (b) have a maximum of about 6000. Blue bar indicates normal expression 
and Red indicates tumour tissue expression. Standard error bars are also shown. 
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Pathway analysis of significantly upregulated proteins 
To identify the pathways in which upregulated proteins were enriched, pathway analysis using 
REACTOME was performed. The 18 significantly upregulated proteins were input into 
REACTOME. Visual assessment of Figure 3.13 show that the significantly upregulated 
proteins were enriched mostly in pathways associated with signal transduction and immune 
system. These pathways include the ErbB and p13/Akt signalling pathways. Interestingly, 
enrichment in signal transduction pathways were also observed in upregulated genes (Table 
3.15). The ErbB signalling pathway was observed to the most upregulated (p= 4.9E-05). The 
proteins, EGFR, ERBB3, and p27 are crucially involved in this signalling pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Diagrammatic representation pathways in which significantly upregulated proteins are 
enriched. Orange lines indicate enriched pathways. Generated from REACTOME software. 
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Table 3.15: Showing Top 10 enriched pathways their p-values and candidate proteins. 
Pathway p-value Candidate proteins 
ErbB signaling pathway 4.9E-05 EGFR, ERBB3, CDKN1B 
MHC class II antigen 
presentation 
5.74E-05 CTSS, CTSB, CTSD 
Diseases of signal transduction 7.68E-05 ERBB3, EGFR, DLL1, 
CDKN1B 
Adaptive immune system 8.14E-05 CTSD, CDKN1B, ERBB3, 
CTSB, CTSS, EGFR 
miR-target in muscle cell-
Tarbase 
1.18E-04 EGFR, CAPG, ERBB3, 
SPARC, CDKN1B 
Trafficking & processing of 
endosomal TLR 
1.3E-04 CTSS, CTSB 
Signalling pathway in 
endosomal TLR 
1.68E-04 EGFR, CDKN1B, ERBB3 
Signalling pathway in 
Glioblastoma 
1.74E-04 EGFR, ERBB3 
P13/AKT signalling in cancer 1.8E-04 ERBB3, EGFR, CDKN1B 
Innate immune system 1.87E-04 CDKN1B, ERBB3, LALS3, 
CTSB 
 
3.7 Protein biomarker discovery and PPI network analysis 
Biomarker discovery 
To identify novel potential protein biomarkers for PDAC the 18 upregulated proteins 
underwent the same filtering process described in section 3.4. This process included the use of 
the Ingenuity pathway analysis software tool in combination with manual filtering process. 
After the filtering processes, ANGPTL4 and p27/kip1 (CDKN1B) were identified as potential 
biomarkers as they bear the hallmarks of a good biomarker (see Section 1.2). 
PPI network analysis of novel potential protein biomarkers 
To understand the roles ANGPTL4 and p27/kip1 play in pancreatic carcinogenesis their PPI 
networks were analysed using the STRING software. The STRING software also generated the 
biological processes, pathways, and molecular functions in which both PPI networks were 
enriched. This analysis further helped in making informed hypothesis on the roles the 
ANGPTL4 and p27/Kip1 may play in PDAC.  
The PPI network show ANGPTL4 is involved in an intricate network of proteins (Figure 3.14). 
Ten proteins were observed to be involved within this PPI network (Table 3.16). All 10 
functional partners are shown to have confidence scores above 0.9. The strongest functional 
interacting partner of ANGPTL4 was observed to be PPARA with a confidence score of 0.990. 
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PPARG and FABP4 follow closely with confidence scores of 0.949 and 0.939 respectively. 
LPL was also shown to be a functional partner with a confidence score of 0.937. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Protein-Protein interaction network of ANGPTL4. The network has a PPI enrichment p- 
value of 4.44E-16. Edges represent various types of interactions as indicated above. Generated from 
STRING. 
 
Table 3.16: Predicted functional partners of ANGPTL4 
Protein 
symbol 
Protein name Confidence 
Score 
PPARA Peroxisome proliferator-activated receptor alpha 0.990 
PPARG Peroxisome proliferator-activated receptor gamma 0.949 
FABP4 Fatty acid binding protein 4 0.939 
LPL Lipoprotein lipase 0.937 
PPARGC1A Peroxisome proliferator-activated receptor gamma, cofactor 1 alpha 0.917 
MED1 Mediator complex subunit 1 0.914 
EP300 E1A binding protein p300 0.908 
CREBBP CREB binding protein 0.907 
NCOR2 Nuclear receptor corepressor 2 0.906 
NCOR1 Nuclear receptor corepressor 1 0.905 
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Cellular lipid metabolism was identified to be the most enriched biological process in the 
ANGPTL4 PP1 network with a false discovery rate of 5.99E-10 (Table 3.17). Ten proteins in 
the PPI network are known or predicted to be involved in cellular lipid metabolism. 
Transcription initiation from RNA polymerase II promoter is 2nd most enriched with a false 
discovery rate of 6.89E-08. Also, important to note is the biological process involve response 
to oxygen levels in which 6 out of 11 PPI network proteins are known or predicted involved.  
Table 3.17: Top 5 biological processes in which the ANGPTL4 PPI network is enriched 
Pathway ID Pathway description Count in gene set False discovery rate 
GO: 0044255 Cellular lipid 
metabolism process 
10 5.99E-10 
GO: 0006367 Transcription initiation 
from RNA polymerase 
II promoter 
7 6.89E-08 
GO: 0044281 Small molecule 
metabolic process 
10 2.08E-06 
GO: 0055088 Lipid homeostasis 5 2.42E-06 
GO: 0070482 Response to oxygen 
levels 
6 6.38E-06 
 
Furthermore, pathways enriched by the ANGPTL4 PPI network were observed. The PPAR 
signalling pathway wasobserved to be the most enriched with 5 proteins being involved (Table 
3.18). The Notch signalling pathways is also shown to be enriched with a false discovery rate 
of 1.34E-04. 
Table 3.18: Top 5 pathways in which the ANGPTL4 PPI network is enriched.  
Kegg Pathway ID Pathway description Count in gene set False discovery rate 
03320 PPAR signalling 
pathway 
5 4.56E-08 
04919 Thyroid hormone 
signalling pathway 
4 4.35E-05 
04330 Notch signalling 
pathway 
3 1.34E-04 
05016 Huntington’s disease 4 1.34E-04 
05169 Epstein-Barr virus 
infection 
3 6.96E-03 
 
Transcription factor activity and binding was observed to be the most enriched molecular 
function with this PPI network with a false discovery rate of 8.09E-08 (Table A11).  
Transcription factor binding followed with 7 out of 11 PPI network proteins being known or 
predicted to be implicated. 
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Similarly, the p27/kip1 PPI network was investigated and 11 functional interacting proteins 
identified (Figure 3.15). All functional interactions of p27/kip1 have confidence scores of 0.999 
(Table 3.19). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Protein-Protein interaction network of CDKN1B/p27. The network has a PPI enrichment 
p- value of 3.03E-06. Edges represent various types of interactions as indicated above. Generated from 
STRING. 
Table 3.19: Predicted functional partners of CDKN1B/p27 
Protein 
symbol 
Protein name Confidence 
Score 
CDK2 Cyclin-dependent kinase 2 0.999 
CDK4 Cyclin-dependent kinase 4 0.999 
CCND1 Cyclin D1 0.999 
SKP2 S-phase kinase associated protein 2 0.999 
CCNE1 Cyclin E1 0.999 
CCND3 Cyclin D3 0.999 
CDK6 Cyclin-dependent kinase 6 0.999 
UBC Ubiquitin C 0.999 
CCNA2 Cyclin A2 0.999 
AKT1 V-akt murine thymoma viral oncogene homolog 1 0.999 
 
The CDKN1B PPI network is mostly enriched in biological processes associated with mitosis 
(Table 3.20). G1/S transition of mitotic cell cycle was observed to be the top most enriched 
biological processes in the PPI network with a false discovery rate of 5.41E-14.   
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Table 3.20: Top 5 biological processes in which the CDKN1B/p27 PPI network is enriched.  
Pathway ID Pathway description Count in gene set False discovery rate 
GO: 0000082 G1/S transition of 
mitotic cell cycle 
9 5.41E-14 
GO: 0044772 Cell cycle phase 
transition 
9 6.16E-12 
GO: 0000278 Cell cycle 9 1.69E-08 
GO: 0051726 Regulation of cell 
cycle 
9 4.71E-08 
GO: 0045787 Positive regulation of 
cell cycle 
7 6.7E-08 
 
The cell cycle was the most enriched in the CDKN1B PPI network with 8 interactors involved 
in the pathway and a false discovery rate of 5.53E-14 (Table 3.22). Pathways involved in viral 
carcinogenesis and small cell lung cancer were also observed to be enriched both with false 
discovery rates of 4.96E-13. 
Table 3.21: Top 5 pathways in which the CDKN1B PPI network is enriched.  
Kegg Pathway ID Pathway description Count in gene set False discovery rate 
04110 Cell cycle 8 5.53E-14 
05203 Viral carcinogenesis 8 4.96E-13 
05222 Small cell lung cancer 7 4.96E-13 
05162 Measles 7 7.8E-12 
05161 Hepatitis B 7 1.06E-11 
 
The top 5 molecular functions enriched in the CDKN1B PPI network were also observed. 
Amongst these, the cyclin-dependent protein serine/threonine kinase regulator activity was the 
most enriched with a false discovery rate of 1.11E-06 and 4 interactors involved (Table A13). 
Furthermore, 7 members of the CDKN1B PPI network were shown to function as kinases. 
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CHAPTER 4- DISCUSSION 
4.1 Overview 
Due to the devastating nature of PDAC, the discovery of biomarkers for pancreatic cancer is 
crucial for diagnostic, prognostic, and therapeutic purposes. In this study, three (ANGPTL4, 
p27 and JUP) novel potential biomarkers of PDAC were identified. Furthermore, validation 
tests performed in this study utilizing multiple tissue samples have shown the overexpression 
of JUP, providing further evidence for its use as a potential biomarker. Also, the use of highly 
sensitive proteome profiler arrays for discovery of ANGPTL4 and p27 validates their 
overexpression in tumours. These identified potential biomarkers exhibit fitting characteristics 
such as: significantly overexpressed in only tumour samples compared to corresponding 
normal tissues and secretion into the bloodstream for easy accessibility in diagnostic testing. 
Importantly, these potential biomarkers are overexpressed in stage I PDAC, suggesting they 
may be useful for early diagnosis. This study suggests that the use of these biomarkers in 
combination may provide increase specificity and sensitivity to PDAC. 
Genetic variations identified by the Ingenuity variant analysis software in SPARC, ZFHX3, 
TGM2 and COLIA1 that are predicted to result to loss of gene function occurring during PDAC. 
It is important to note that this is the first pancreatic cancer study that reports variations in some 
of these gene (i.e. ZFHX3, TGM2 and COLIA1). These genes have been observed to play 
tumour suppressive roles. In several other cancers, they have been identified to induce cell 
death. I propose that the reinstating of the normal functions in these genes by providing targeted 
therapies, might result to the inhibition of pancreatic tumorigenesis.  
Furthermore, the present study shows the dysregulation of several signalling pathways such as 
IGF/MAPK, integrin, and Ras. Dysregulation would result in aberrant biological processes. It 
is possible that these pathways play critical roles in propagating pancreatic tumorigenesis and 
that targeting them might be beneficial for PDAC treatment.  
I also identified the downregulation of CXXC4, GALNT1, HS3ST4, SLC15A4, and TSPAN7 
during pancreatic cancer and hypothesize that this drives tumorigenesis. These genes are 
known to be involved in the inhibition of cellular proliferation and survival. Targeting them 
for potential drug discovery might prove beneficial 
Finally, this study reveals the upregulation of genes involved in the necroptic and immune 
system pathways in tumours. Necrosis in tumours has been observed to result in poor outcomes 
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for cancer patients. Therefore, necrosis in tissues may be way of determining outcome in 
pancreatic cancer patients thereby enabling the use of targeted therapies for treatment.  
The immune system is activated during PDAC; however, cancer cells have developed several 
mechanisms to circumvent detection. This study has identified the activation of some of these 
mechanisms including: the upregulation of VEGF and cathepsin S corroborating others that 
have identified this during tumorigenesis. These upregulations may lead to blocking of anti-
tumorigenic functions of the immune system. 
In the following sections I discuss in detail the above findings of this study 
4.2 Novel potential biomarkers of PDAC 
A biomarker (biological marker) functions as an indicator of a diseased state. It can also help 
in the monitoring of the progression of a disease and a patient’s response to treatment. The 
characteristics of a good biomarker have been well described (Section 1.2). Due to the 
aggressive nature of PDAC, there is urgent need for biomarkers in diagnosis and prognosis. In 
this study, I have identified 3 novel potential biomarkers of PDAC using highly sensitive and 
high throughput discovery and validation techniques. Importantly, I have employed a series of 
processing methods to ensure high sample quality.  Furthermore, the identified potential 
biomarkers meet the hallmarks of a good biomarker (also described in Section 1.2) including; 
being secreted in the blood (for easy accessibility) and differentially expressed in normal and 
tumour samples. I describe these identified potential biomarkers below stating supporting 
reasons for their proposition as candidate for early diagnostic testing. 
Junction plakoglobin (JUP) 
In this study, RNA sequencing was utilized for differential gene expression analysis. The 4911 
upregulated genes then went through a biomarker filtering process involving the use of the IPA 
software that identified potential biomarkers. Validation test with additional tumours (n=5) and 
their corresponding normal tissues (n=5) was also conducted using real time PCR. This led to 
the identification of JUP as being upregulated in tumour samples but not in normal tissues.  
Junction plakoglobin (JUP) gene encodes an important cytoplasmic protein called plakoglobin 
(also known as γ catenin). JUP functions in cell-cell adhesion as an important component of 
desmosomes and adherens junction. Furthermore, JUP is expressed in the blood making it 
easily accessible to be measured (Cooksley-Decasper et al., 2012). The easy accessibility of 
biomarkers is crucial as it enables for less invasive ways of testing for a diseased state. 
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Additionally, the observed overexpression of JUP observed in this study in all tumours but not 
in corresponding normal tissues might be indicative of its specificity to PDAC, further 
signifying its role as a biomarker of PDAC. Importantly, tumour samples used in this study for 
both discovery (RNA sequencing) and validation (real time PCR) tests were from early stage 
(stage I) PDAC patients. The overexpression of JUP in early stage PDAC is a critical 
characteristic for its proposed role as a potential diagnostic biomarker.   
This study contradicts others in which the underexpression of JUP was observed in pancreatic 
tumours and cell lines (Pryczynicz et al., 2010; Toyoda et al., 2005). This contradiction might 
be because in this study, samples from black South African population were used and gene 
expression profiles are known to vary amongst population groups (Storey et al., 2007). As this 
seem to be the first study to profile extensively genes in pancreatic tumours obtained from any 
black African PDAC patient, I suggest that this observed overexpression might be unique to 
the population group, however, more validation tests are needed to confirm this. Also, the 
method of discovery used in other studies differ with the present one and this might result in 
contradicting results. This study however resonates with others done with testicular germ cell 
tumours in which an overexpression of JUP was identified (Skotheim et al., 2003). Although, 
JUP was observed to be overexpressed in testicular germ cell tumours, it could still be used in 
combination with other potential biomarkers identified in this study for early diagnostic PDAC 
testing. This combination might enhance sensitivity and specificity for PDAC detection 
This study has identified JUP as a potential biomarker for PDAC. Future studies with a much 
larger sample amount should be done to further verify this potential biomarker.  Additionally, 
the use biological samples such as blood from different stages of PDAC to observe the 
expression pattern of JUP as the tumour progresses might prove useful to corroborate these 
findings.   
Angiopoietin-like 4 (ANGPTL4)  
The Human Oncology Proteome Profiler Array allowed for the focused analysis of protein 
expression. The highly sensitive and specific array panel was used to compare protein 
expression profile in normal and tumour samples. The 18 significantly upregulated proteins 
observed in this study were then subjected to the filtering process (Section 2.2.8). This process 
then identified ANGPTL4 as a potential biomarker for PDAC.  
ANGPTL4 is a member of the ANGPTL protein family. The ANGPTL4 gene encodes a 
glycoprotein with a mass of approximately 45-65kDa. Importantly, this study showed that 
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ANGPTL4 was significantly (p=3.958E-02) overexpressed in all tumour samples but not in 
corresponding normal tissues. As the samples used were obtained from early stage (stage I) 
PDAC patients, this overexpression of ANGPTL4 in tumour tissues might indicate its role as 
a diagnostic biomarker. Also, the use of the highly sensitive proteome profiler array and the 
overexpression of ANGPTL4 in all tumour samples further supports its specificity and 
sensitivity to PDAC. Additionally, ANGPTL4 has been observed to be secreted and expressed 
in the blood (Mandard et al., 2004). This makes it easily accessible and a good candidate 
biomarker.   
Furthermore, the significant upregulation of ANGPTL4 in early stage pancreatic tumour 
suggests that it plays an important role in tumorigenesis. Although there have been conflicting 
reports over the years growing evidence show that ANGPTL4 plays a pro-tumorigenic role 
(Shibata et al., 2010). Shibita and colleagues observed the overexpression of ANGPTL4 
oesophageal carcinoma and the levels increase as tumour develop from benign to malignant 
status. This suggests that ANGPTL4 expression levels could be used to predict prognosis in 
carcinoma cells.  
Tumours produce an increased amount of reactive oxygen species. However, these tumours 
develop a strategy to escape death by anoikis. Anoikis is a type of programmed cell death in 
which certain cells die when separated from the extracellular matrix. This anoikis-resistance in 
crucial to tumorigenesis. A study showed that ANGPTL4 instigated anoikis resistance to 
tumour cells (Shibata et al., 2010). Overexpression of ANGPTL4 implies increased anoikis 
resistance in tumour cells enabling cells to survive and migrate uncontrollably. 
Additionally, PPI network analysis using STRING software helped to identify possible roles 
of ANGPTL4 in PDAC. The analysis showed that ANGPTL4 plays a role in PPAR signalling 
pathway (Table 3.18). The PPAR family members are known to regulate the expression of 
ANGPTL4 (Georgiadi et al., 2010; Kersten et al., 2009) and are known to play crucial roles in 
lipid homeostasis and metabolism (Kersten, 2005). They have also been observed to be 
involved in tumorigenesis. With its interaction with the PPAR family, ANGPTL4 is implicated 
in tumorigenesis, however, there is still no evidence that the PPAR family induces the 
overexpression of ANGPTL4. 
PPI network analysis also showed ANGPTL4 plays a role in lipid metabolism (Table 3.17). 
ANGPTL4 is known to inhibit lipoprotein (LPL) the enzyme responsible for the hydrolysis of 
triacylglycerols (TAGs). This inhibition by ANGPTL4, prevents the removal of circulating 
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triacylglyerols. ANGPTL4 impedes LPL by converting active lipoprotein dimers to their 
inactive form- monomers. The upregulation of ANGPTL4 results in an increase in circulating 
triacylglycerols whereas, a downregulation results in a decrease of TAGs (Zhu et al., 2012). 
An increase in triacylglycerol level can result in the inflammation of the pancreas observed in 
pancreatitis which is known to increase the risk of pancreatic cancer. 
The significant upregulation of ANGPTL4 in early stage PDAC hints on its role as a potential 
diagnostic biomarker. Although, highly a sensitive technique was used for the discovery of 
ANGPTL4 as a potential biomarker, future validation tests are crucial to corroborating these 
findings. Future validation tests should include the use of easily accessible blood samples like 
blood and a much larger sample number.   
p27/kip1 
As described above in the ANGPTL4 section, the Human Oncology Proteome Profiler Array 
was used for differential protein expression analysis. From 18 significantly upregulated 
proteins p27 was identified as potential biomarker by the IPA software. This study show that 
p27 is significantly overexpressed in tumour tissues compared to normal ones. This 
overexpression was observed in all tumour samples indicating its sensitivity to PDAC. Also, 
p27 has been identified as a secretory protein (Fero et al., 1998) and its presence in the plasma 
makes it a potential candidate biomarker. Also, as described previously all tumour samples 
were obtained from stage I PDAC patients and the overexpression of p27 might indicate its 
used as an early indicator of PDAC. 
p27 is encoded by the CDKN1B gene and acts as tumour suppressor protein. It functions in 
regulating the cell cycle at the G0 to S phase transitions. p27 carries out its roles by binding 
and modulating the actions of cyclin-dependent kinases (CDKs) (Sherr and Roberts, 1999) . 
Increased levels of active tumour suppressor proteins like p27 usually correlate to cancerous 
cell deaths. Most tumours in several human organs (including lung, stomach, liver, colon, and 
breast) show a reduction in p27 expression due to proteasomal degradation (Chu et al., 2008). 
This reduction usually correlates to poor prognosis. In this study, I have observed the 
significant (p=5.966E-03) upregulation of p27 in all stage I PDAC tumour tissues (Table 3.14, 
Figure 3.12) and propose its function as a novel potential diagnostic biomarker.  
In most tumours, p27 is inactivated by mislocalization from the nucleus to the cytoplasm and 
phosphorylation (Lee and Kim, 2009). Phosphorylation of p27 at the Thr157 and Thr198 by 
Akt enables it to form a complex with cyclin D and CDK4. In tumour cells, active p27-cyclin 
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D-CDK4 accumulates in the cytoplasm (Soos et al., 1996). Oncogenic stimulation of MAP2K, 
Akt, and Ras (Cheng et al., 1998; Liu et al., 2000; Viglietto et al., 2002) signalling pathways 
is responsible for this. Interestingly, this present study showed that these pathways are 
upregulated in pancreatic tumours (Table 3.7, 3.21) indicating that they might be involved in 
the inactivation of p27. Although p27 is observed to be upregulated in this study, the 
upregulation of its inactivators may render it non-functional and therefore as good as a reduced 
one. Additionally, germline mutations in p27 can render it inactive. These mutations have been 
observed in breast cancers (Chappuis et al., 2000) and endocrine neoplasms (Pellegata et al., 
2006). The suggested inactivation of p27 may be responsible for its overexpression in PDAC 
tumours which makes it a potential biomarker.  
The significant upregulation of p27 in all stage I tumours observed in this study, is 
characteristic of a potential diagnostic biomarker, however, further validation studies are 
necessary to support this claim.  
4.3 Genetic variants might induce tumorigenesis 
Variations in genes might affect the roles they play in biological processes and signalling 
pathways. Variations in certain genes may lead to uncontrolled cellular proliferation and 
tumour invasion. For example, the inactivation of tumour suppressive genes due to loss of gene 
function is characteristic of cancerous cells (Hanahan and Weinberg, 2000). These mutations 
can result from genetic single nucleotide polymorphisms, histone modifications and DNA 
methylations (Berdasco and Esteller, 2010; Esteller, 2007; Jones and Baylin, 2007). In PDAC, 
some gene alterations result in loss of gene function driving carcinogenesis.  
In this study, variant calling was performed from RNA sequencing to produce VCF (variant 
calling files) for each sample which were interrogated to identified novel genetic variants. Files 
were then uploaded into Ingenuity Variant Analysis software tool. Six variants were identified 
in 4 genes and in all tumour samples. These variants were only present in tumour samples and 
not in their corresponding normal tissues. They include: insertions, deletions, and single 
nucleotide variations, all of which are predicted (by the IVA software tool) to result in a loss 
of gene function.  The identified genes have been described in detail below. 
Secreted protein acidic and rich in cysteine (SPARC) 
An insertion at the exonic region of SPARC at position 151043159 (Chr 5) causes a frameshift 
mutation predicted to result in loss of gene function has been observed in pancreatic tumours 
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(Table 3.13). Notably, this mutation was observed in stage I PDAC tumours suggesting that it 
might play a role in inducing and enhancing pancreatic tumorigenesis. This result resonates 
with several studies suggesting that a deletion or mutation in SPARC is a critical feature 
premalignant lesions of the pancreas (Vaz et al., 2015). Importantly, variant analysis in this 
study identify SPARC as a cancer therapeutic target suggesting it might be of significance 
during carcinogenesis.  
SPARC gene encodes osteonectin (SPARC), a glycoprotein belonging to a group of 
matricellular proteins. It is multifunctional and involved in an array of biological processes 
including development, cell adhesion, cellular differentiation, and proliferation. Although its 
role in cancer is not fully understood, it has been reported to function in angiogenesis, 
apoptosis, and cellular proliferation (Rossi et al., 2016; Vaz et al., 2015).  
Furthermore, the hypermethylation of SPARC, which silences the gene, at the CPG islands in 
pancreatic cancer cell lines has been identified (Nagaraju and El-Rayes, 2013). Hahn and 
colleagues also observed that a loss of heterozygosity in SPARC results in the inactivation of 
the gene and this was found to occur in 20% of pancreatic tumours (Hahn et al., 1995). This 
further reiterates the role anti-tumorigenic role of SPARC in pancreatic cancer and that a loss 
of its function drives tumorigenesis. 
Additionally, Mao and colleagues hypothesized that SPARC induces the overexpression of p53 
consequently resulting in cell cycle arrest at the G1/S phase (Mao et al., 2014). SPARC was 
also shown to be involved in the inhibition of angiogenesis in pancreatic cancer thereby 
resulting in decreased tumour growth. It carries out this function by downregulating the 
oncogenic VEGF (Jendraschak and Sage, 1996). However, in this study I have observed an 
upregulation of the VEGF signalling pathway suggesting that this might not be the case (Table 
3.3).  
This study has identified a frameshift variation in SPARC that may result in loss of gene 
function. Due to its anti-tumorigenic effect (observed in other studies), the loss of SPARC can 
be linked to the induction of carcinogenesis and this makes it a potential therapeutic target. 
Thus, future studies with a large sample number is crucial to validating this mutation and 
further linking it to carcinogenesis. 
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Zinc finger homeobox 3 (ZFHX3) 
ZFHX3 was identified to be a suppressor of AFP (alpha- fetoprotein) by binding the AP-rich 
region of the gene (Zhang et al., 2005). ZFHX3 has been observed to play anti-tumorigenic 
roles in different cancers. I have shown that a deletion in the exonic region of ZFHX3 causes a 
frameshift mutation that may result in loss of gene function (Table 3.13). In this study, this 
mutation was only observed in pancreatic tumours and not in normal tissues. It is possible that 
a loss of gene function in ZFHX3 might help to induce carcinogenesis. 
The inactivation of ZFHX3 has been observed in several cancers. Studies in mice have done by 
Sun et al showed that a deletion of ZFHX3 resulted in growth of pancreatic tumours (Sun et 
al., 2014). They observed that deleting ZFHX3 resulted in the dysregulation of multiple 
signalling pathways including Akt - which I observed to be upregulated in our study (Table 
3.21). The dysregulation of the Akt pathway can enhance tumorigenesis (see Section 4.4 
below) 
Christopher and colleagues observed the silencing of ZFHX3 in endometrial cancers. They 
observed that a loss of ZFHX3 results in poor prognosis in endometrial cancers (Walker et al., 
2015). In gastric cancer, the absence of ZFHX3 resulted in the expression of AFP (Kataoka et 
al., 2001). AFP is known to be involved in invasive and malignant gastric cancer. ZFHX3 was 
also found  to inhibit the transcription of the oncoprotein-Myb (Kaspar et al., 1999). Therefore, 
a loss of ZFHX3 might enhance carcinogenesis. There is evidence that by interacting with 
PIAS3, ZFHX3 induces the downregulation of the STAT3 signalling pathway (Nojiri et al., 
2004). This pathway plays a role in inducing oncogenesis. 
As far as can be determined, this study is the first of its kind to identify a mutation in ZFHX3 
in human pancreatic tumours. The loss of gene function resulting from this mutation might help 
to drive carcinogenesis. Therefore, the role of ZFHX3 in PDAC development should be 
investigated further as it might have therapeutic benefits. 
Transglutaminase 2 (TGM2) 
In this study, it was observed that in tumours a single nucleotide variation occurring at the 
splice site if TGM2 was predicted to result in a loss of gene function (Table 3.13). I propose 
that this loss of gene function (predicted by the IVA software) might help drive pancreatic 
carcinogenesis. This proposition stems from previous cancer studies indicating the pro-
apoptotic function of TGM2. Importantly, TGM2 was observed in this study to be 
overexpressed, however, the identified mutation seems to have rendered it non-functional. An 
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overexpression in TGM2 might hinder pancreatic tumorigenesis but if the gene has lost its 
function, it cannot play its pro-apoptotic role.   
TGM2 gene encodes a multifunctional protein (TGM2) playing several roles within and outside 
the cell (Mehta, 2008). It is known to play pro-apoptotic (Rodolfo et al., 2004) roles in 
carcinogenesis. Fok and Mehta showed that TGM2 induced apoptosis in an AIF (apoptosis 
inducing factor) and caspase independent manner (Fok and Mehta, 2007). They observed that 
TGM2 induced swift apoptosis in pancreatic cancer cell lines and this was linked with 
translocation of AIF from the mitochondria to the nucleus driving caspase dependent apoptosis. 
Furthermore, TGM2 was observed to interacting with the pro-apoptotic Bax to induce apoptosis 
in neuroblastoma cells (Rodolfo et al., 2004). They further observed that mutations in TGM2-
BH3 domain resulted in the loss of inducing ability of TGM2. These studies show that TGM2 
induces apoptosis in cancer cells, its non-functionality may result in an inhibition of apoptosis. 
TGM2 is also associated with chemotherapeutic resistance in pancreatic cancer. It is highly 
expressed in pancreatic tumours and this upregulation is associated with invasion, metastasis, 
and poor clinical outcomes. Thus, it has been suggested to be a potential therapeutic target in 
pancreatic cancer (Mehta, 2008).  
TGM2 has been observed to play pro-apoptotic roles in carcinogenesis. Its predicted loss of 
function in pancreatic tumours observed in this study suggests for further investigation.  
Collagen type I alpha 1 (COLIA1) 
I have shown that in pancreatic tumours there are variations in the COLIA1 gene at 3 different 
splice sites may result in a loss of gene function (Table 3.13). COLIA1 is a gene that encodes 
the protein collagen type I, alpha 1. Collagen supports and toughens multiple tissues including 
bones, skin, sclera, and cartilages. There have been no studies on COLIA1 in cancer, however, 
its deficiency has been linked to several bone diseases. For example, polymorphisms in 
COLIA1 were observed to relate to osteoporotic fractures (Alvarez-Hernandez et al., 2003). 
The role of COLIA1 in carcinogenesis has not been elucidated, it might prove useful to 
investigate its function during tumour progression. 
4.4 Dysregulated pathways that induce PDAC progression 
RNA sequencing showed the upregulation of 4911 genes. Pathway analysis using the 
PANTHER software identified significantly upregulated pathways. Similarly, differential 
protein expression data obtained from the Human Oncology Proteome Profiler Array identified 
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18 significantly upregulated proteins. Pathway analysis of these proteins also identified 
upregulated pathways. It is important to note that the samples used for these expression profiles 
where obtained from stage I PDAC patients indicating that aberrancy in the identified pathways 
occur at the early stages of PDAC. 
Amongst the pathways identified from the analysis of the gene and protein expression profiles 
are those involved in the hallmarks of cancer. These six hallmarks include: avoiding growth 
suppressors, opposing cell death, triggering angiogenesis, sustaining proliferative signalling, 
aiding replicative immortality, and activating invasion and metastasis (Hanahan and Weinberg, 
2000).  I describe these dysregulated pathways and the role they may play in the induction and 
enhancement of pancreatic tumorigenesis 
Insulin/IGF pathway-mitogen activated protein kinase/MAP kinase cascade 
IGF (Insulin growth factor) signalling is important for tissue development and integrity. It 
functions in inducing cellular proliferation and inhibiting apoptosis (LeRoith and Roberts Jr, 
2003). It can cascade with MAPK (Mitogen activated protein kinase) to further induce the 
above-mentioned biological processes. MAPK signalling is crucial to the cell as it connects 
external signals to the system that regulates cell growth, differentiation, proliferation and 
migration (Denduluri et al., 2015). Dysregulation of the IGF/MAPK signalling pathway have 
been observed in various cancers including pancreatic cancer (Denduluri et al., 2015; Sachdev 
and Yee, 2007). In this study, I observed that the IGF/MAPK signalling pathway was the most 
enriched by the upregulated genes (Table 3.3) suggesting its involvement during pancreatic 
tumour progression. A previous study observed that IGF signalling enhances cellular 
proliferation and growth through the Ras/MAPK pathway. In glioma stem cells, it was shown 
that IGF signalling activates MAPK leading to heightened cellular proliferation (LeRoith and 
Roberts Jr, 2003). Furthermore, MAPK signalling is known to induce the expression of 
downstream genes associated with cellular growth, proliferation and mitosis (Brunet et al., 
1999; Furukawa et al., 2006).  
One major reason for the poor survival statistics of PDAC patients is drug resistance during 
chemotherapeutic treatment. PDAC patients (including those used for this study) are treated 
with gemcitabine even though their survival rate is poor. IGF signalling has been implicated in 
resistance to the drug, gemcitabine, used in pancreatic cancer treatment (Tian et al., 2013). 
Drawing from the observations of Tian and colleagues, the upregulation observed in this study 
is indicative of gemcitabine resistance in PDAC patients undergoing treatment.  
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This study corroborates the amplification of the IGF/MAPK signalling pathway during 
pancreatic cancer progression observed in previous studies. Other studies have linked this 
amplification to the enhancement of tumourigenesis and drug resistance. Thus, I suggest that 
this pathway plays a crucial role during pancreatic tumorigenesis and that the discovery and 
utilization of inhibitors of this pathway might be crucial in finding better ways of pancreatic 
cancer treatment.   
Integrin signalling pathway 
The integrins are a group of cell adhesion regulators involved in an array of biological 
processes crucial for tumour initiation, advancement, and metastasis (Jones and Walker, 1999). 
In this study, I observed the upregulation of the integrin signalling pathway (Table 3.3) 
signifying its possible involvement in tumorigenesis. This upregulation was also observed in 
pancreatic cancer studies where it was associated with poor prognosis and chemotherapeutic 
resistance (Desgrosellier and Cheresh, 2010). When pancreatic cancer cells undergo 
chemotherapy, they induce the expression of L1CAM-an anti-apoptotic cell adhesion 
molecule. However, L1CAM binds  α5β1 integrin-a component of the integrin signalling 
pathway resulting to chemotherapeutic resistance (Kiefel et al., 2010). Furthermore, the 
integrin signalling pathway induces the protection of pancreatic cancer cells by pancreatic 
stellate cells from radiotherapy-induced apoptosis (Mantoni et al., 2011) signifying it also plays 
a role in radiotherapeutic resistance. 
The upregulation of the integrin signalling pathway in pancreatic tumours observed in this 
study suggests its role in PDAC progression. This role has been observed in other studies. 
Additionally, might be a good target for future pancreatic cancer treatment because of its role 
in inducing therapeutic resistance.  
Ras pathway 
The Ras family (H-Ras, K-Ras, and N-Ras) are proto-oncogenes known to be involved in 
multiple cellular processes. K-Ras is required for cellular growth control and its mutation have 
been identified in about 90% of pancreatic cancers (LeBleu et al., 2013; Nicke et al., 1999). 
Ras becomes activated when it binds to GTP (guanidine tri-phosphate) and is inactivated when 
ATP is hydrolysed (Logsdon and Lu, 2016). This hydrolysis is however impaired in Ras 
mutants. The Ras signalling pathway can be regulated by multiple external stimuli including; 
inflammation (Logsdon and Lu, 2016), receptor tyrosine kinases (Buday and Downward, 
2008), and G-protein coupled receptors (Almendro et al., 2010). Importantly, in this study I 
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have observed the overexpression of one of these external stimuli- receptor tyrosine kinases 
(see EGFR signalling pathway). The receptor tyrosine kinases induce the Ras signalling 
pathway and an overexpression of these kinases suggests stimulation of the Ras signalling 
pathway. Furthermore, I observed the upregulation of the Ras signalling pathway in pancreatic 
tumours (Table 3.3) indicating they might play a role in enhancing tumorigenesis. This 
corroborates the study by Delire and Starkel in which they showed that the upregulation of the 
Ras signalling pathway, not just mutation of K-Ras, induces carcinogenesis (Delire and Starkel, 
2015). 
This present study observed the upregulation of the Ras pathway in PDAC tumours and I 
propose it aids in enhancing tumorigenesis. Future studies targeting components of this 
pathway might prove a good strategy for the inhibition pancreatic tumorigenesis. 
CCKR signalling pathway 
CCKR signalling has been observed to play a role in enhancing pancreatic tumour growth and 
development (Smith et al., 2016). CCKR (Cholecystokinin) is highly upregulated in pancreatic 
cancer cell lines (Smith et al., 1994). When CCKR is activated by CCK or gastrin (Smith et al., 
1995, 1990), it can induce the Akt pathway which results in cellular proliferation (Dufresne et 
al., 2006). Interestingly, I have observed the upregulation of both the CCKR and p13k/Akt 
signalling pathways in pancreatic tumours (Table 3.7, 3.15). The upregulation of CCKR 
signalling pathway might be involved in the induction of the p13k/Akt signalling pathway 
which might then drive tumorigenesis. 
Other studies have linked the overexpression of the CCKR signalling pathway to pancreatic 
tumorigenesis (Weinberg et al., 1997). In this study, I have corroborated this overexpression.  
Numerous antagonist of CCKR are being developed -with promising effects-  to block binding 
to CCK and gastrin, thereby inhibiting the CCKR signalling pathway (Berna and Jensen, 2007). 
These developments further show the role of the CCKR signalling pathway in enhancing 
tumour growth and may be a good step to improving strategies in treating PDAC. 
PDGF signalling pathway 
The isoforms of PDGF (platelet derived growth factor) induce cell survival, growth, and 
migration. In tumorigenesis, they play a role in stimulating cellular proliferation and thus its 
overexpression correlates with tumour invasion (Pietras et al., 2003). In this study, it was 
observed that the PDGF signalling pathway is upregulated in pancreatic tumour (Table 3.3) 
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indicating they might be involved in tumour initiation. This upregulation was also observed by 
Matthias and colleagues in pancreatic cancer cell lines (Longati et al., 2013). Blocking 
PDGFRb prevents pancreatic cancer invasion and metastasis further reiterating the importance 
of the PDGF signalling pathway in pancreatic cancer progression (Weissmueller et al., 2014). 
Furthermore, studies in breast cancer cells, have linked the PDGF signalling pathway to 
tumorigenesis. PDGF induces the proliferation of myofibroblast-like cells and overproduction 
of ECM (extracellular matrix) resulting in tumorigenesis (Shao et al., 2000).  
Taken together observations from this study and other ones, the upregulation of the PDGF 
signalling pathway in PDAC tumours shows it might be involved in tumour advancement; 
therefore, targeting the components of this pathway might prove useful in therapy. 
EGF receptor signalling 
In this study, it was observed that the EGFR signalling pathway is overexpressed in PDAC 
tumours (Table 3.3) indicating it might play a role in cancer development. Epidermal growth 
factor receptor (EGFR) also known as ErbB1 is a transmembrane tyrosine kinase. It is activated 
by the binding of its ligands, TGF-α (Transform growth factor α) and EGF. EGFR is known to 
be upregulated in approximately 90% of pancreatic tumours (Troiani et al., 2012). Several 
pancreatic cancer studies have targeted the EGFR signalling pathway for chemotherapeutic 
purposes. When pancreatic cancer cell lines are exposed to gemcitabine, it resulted to increased 
phosphorylation (Morgan et al., 2008) which can be hindered by EGFR inhibitors leading to 
apoptosis (Bruns et al., 2000). Erlotinib is the only FDA approved EGFR inhibitor administered 
to manage pancreatic cancer progression, however, there is little progress in patient prognosis. 
Multiple mechanisms initiate this resistance including EGFR initiated activation of 
downstream mediators (Guix et al., 2008). In this study, I observed two of these mediators, 
they include: activating mutations in KRas and upregulating P13K-Akt signalling pathways-
which I have observed in this study (Table 3.15). 
Furthermore, the upregulation of ErbB3 -a component of the EGFR signalling pathway-was 
also observed in pancreatic tumours (Table 3.15) indicating it might be involved in driving 
tumour growth. This observation supports those of other studies in which the ErbB signalling 
pathway was observed to be upregulated. For example, the overexpression of ErbB2 has been 
observed in breast, ovarian and pancreatic cancers- where it also confers chemoresistance to 
cancer cells (de Graeff et al., 2008; Hynes and MacDonald, 2009; Skrypek et al., 2015). The 
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upregulation of ErbB3 has also been observed in pancreatic cancer cell lines (Friess, 1995) and 
tumours (Liles et al., 2010) where it induces tumorigenesis.  
The ErbB receptor kinase family function crucially in various physiological process in normal 
and cancerous cells. They include EGFR, ErbB2, ErbB3 and ErbB4 (Hynes and MacDonald, 
2009). The expression of members of the ErbB signalling pathway have been observed to 
enhance carcinogenesis. It was commonly thought that ErbB3 played a role in cellular 
proliferation by acting as a scaffold agent to EGFR and ErbB2 (Sithanandam and Anderson, 
2008). This was mostly due to the evidence that the EGFR-ErbB3 heterodimer drives tumour 
progression (Engelman et al., 2005; Soler et al., 2009; Ueno et al., 2008). It is important to note 
that I have also observed the overexpression of EGFR indicating that it might function together 
with ErbB3 to induce tumorigenesis. However, Liles and colleagues showed that the 
overexpression ErbB3 alone is sufficient to induce cellular proliferation (Liles et al., 2010) and 
that its silencing decreases cell growth proliferation (Frolov et al., 2007). Furthermore, ErbB3 
was identified to be involved in the P13K/Akt signalling pathway and this association further 
induces cellular proliferation (Jones et al., 2006). 
Additionally, ErbB3 also confers radioresistance on cancer cells induced by HSP90 inhibitors- 
a strategy used in chemotherapy for cancers in which ErbB2 is overexpressed (Dote et al., 
2005). ErbB3 is chiefly responsible for conferring cellular resistance to ErRB2 and EGFR 
inhibitor therapies. 
The expression of components of the EGFR signalling pathway in pancreatic cancer play a role 
in metastasis and tumour occurrence (Tobita et al., 2003) and taken together the above 
observations more studies are needed to produce better EGFR inhibitors. 
p13k/Akt signalling pathway 
In this study, I have observed the upregulation of the p13K/Akt signalling pathway in 
pancreatic tumours (Table 3.15) indicating it plays a role in tumour progression. Amongst the 
components of this pathway I observed to be overexpressed is EGFR and ErbB3. Both proteins 
have been identified to induce the p13K/Akt signalling pathway (Guix et al., 2008; Jones et al., 
2006). Furthermore, the CCKRs can also induce P13K/Akt signalling (Dufresne et al., 2006) 
and I have shown in this study the enrichment of the CCKR signalling pathway (see CCKR 
signalling pathway section for further description). 
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 p13k (Phosphoinositide 3-kinases) are known to be hyperactive during tumorigenesis. 
Activation of p13k occur downstream GPCR (G-protein coupled receptors) and tyrosine 
receptor kinases (RTK). p13Ks induce mTOR (mammalian target of rapamycin) via Akt 
(Martini et al., 2014). The aberrant signalling of the p13K/Akt pathway is observed in majority 
of human tumours and is known to be responsible for drug resistance in chemotherapy. The 
overexpression of various components of p13k/Akt pathway has also been shown (Martini et 
al., 2014). Akt2- a member of the Akt kinase family- was shown to be upregulated in pancreatic 
cancer (Ndubaku et al., 2013) suggesting its role in the induction of carcinogenesis.  
The overexpression of the p13K/Akt signalling pathway during pancreatic tumorigenesis is 
corroborated in this study. Its role in enhancing tumour growth and chemoresistance has also 
been observed in other studies. Thus, the development of antagonists for the p13K/Akt 
signalling pathway and its inducers is a promising area for the treatment and management for 
PDAC. 
Angiogenesis- the role of VEGF signalling pathway 
In the current study, I have observed the overexpression of the VEGF signalling pathways in 
pancreatic tumours indicating it might play a role in propagating pancreatic tumorigenesis 
(Table 3.3). Since the VEGF signalling pathway is known to regulate angiogenesis, an 
overexpression of this pathway leads to increased angiogenesis. This increase consequently 
results in tumour invasion and metastasis. 
Inducing angiogenesis- the production of new blood vessels- is one of the hallmarks of cancer 
Tumours as in normal tissues require the supply of oxygen and adequate nutrients to survive 
and they require an avenue for the removal of waste products. Blood vessels formed by the 
process of angiogenesis help provide this avenue. During tumorigenesis, the angiogenic 
process is always active, consequently leading to the uncontrollable production of new blood 
vessels which aids in tumour invasion and metastasis (Hanahan and Folkman, 1996). 
Angiogenesis in tumour cells is mostly mediated by VEGF-A (Folkman, 1990). The production 
of VEGF-A (vascular permeability growth factor) has been shown to be involved in 
tumorigenesis (Ferrara, 1999) and pancreatic cancer cells secrete bioactive VEGF A (Luo, 
2001). Furthermore, the expression of VEGF-A is upregulated in several carcinomas including 
pancreatic cancer (Itakura, 1997) and has been observed to confer radioresistance to cancer 
cells (Gupta, 2002).  
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These findings reiterate those of other studies observing the overexpression of the VEGF 
signalling pathway in pancreatic tumorigenesis. This pathway is known to induce angiogenesis 
thereby enhance tumour growth. The pro-angiogenic, pro-tumorigenic and radioresistance role 
of VEGF signalling pathway makes it a viable target for therapy. Indeed, anti-angiogenic 
therapy have been shown to decrease tumour growth and metastasis is pancreatic cancer animal 
models (Hotz, 2001). 
 
4.5 Downregulation of crucial genes aid PDAC progression 
Using RNA sequencing, differential gene expression analysis was performed. I observed 5 
downregulated genes in pancreatic tumours but not in their corresponding normal tissues. The 
downregulation of genes that play anti-tumorigenic roles can occur during carcinogenesis. 
Below, I have described the identified genes observed to be downregulated in PDAC tumours. 
CXXXC Finger protein 4 (CXXC4) 
This study has observed the downregulation of CXXC4 in pancreatic tumours (Table A10) and 
further propose they might play a role in inhibiting tumorigenesis. This proposition stems from 
work done on gastric cancer in which it was observed that CXXC4 functions as a tumour 
suppressor and might be a prognostic factor for the disease (Lu et al., 2013). Kojima and 
colleagues also observed that in renal cell carcinoma, a downregulation of CXXC4 resulted in 
the induction of cellular proliferation, survival, and malignancy by the activation of the Wnt 
signalling pathway (Kojima et al., 1993). CXXC4 encodes a CXXC-type zinc finger domain 
that inhibits the WNT signalling pathway (implicated in cancer progression) by binding to 
dishevelled (dvl) and consequently stabilizing the β catenin destruction complex.  
 Since CXXC4 blocks the WNT pathway (which is known to drive carcinogenesis), thus, its 
downregulation might enable the upregulation of this pathway. Possibly, the upregulation of 
CXXC4 might lead to a down regulation of Wnt pathway subsequently enabling the progression 
of pancreatic cancer was observed by Lu et al in gastric cancer and Kojima et al in renal cell 
carcinoma (Kojima et al., 1993; Lu et al., 2013).  
This study has shown the downregulation of CXXC4 in pancreatic tumours. Drawing from 
observations from work done on other cancers this downregulation might aid tumorigenesis. 
Future studies on the effect of the expression of CXXC4 in pancreatic cancer are needed.  
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Polypeptide N-actylgalactosaminyltransferase 1 (GALNT1) 
I observed a downregulation of GALNT1 (Table A10 Appendix) in pancreatic tumours. 
Although there are no studies on GALNT1 in pancreatic cancer cells however, some work has 
been done in other cancers. These studies observe the overexpression of GALNT1 and its link 
it to carcinogenesis. Ding and colleagues observed the overexpression of GALNT1 in bladder 
cancer and suggested its role as a potential biomarker. Furthermore, silencing GALNT1 in 
bladder cancer resulted in the inhibition of cellular proliferation and tumour growth (Ding et 
al., 2012). In hepatocellular carcinoma, knockdown of GALNT1 inhibited malignancy via the 
downregulation of the EGFR signalling pathway suggesting its role as an oncogene (Huang et 
al., 2015). Huang and colleagues observed that the knockdown of GALNT1 results in anti-
malignancy but this is through the downregulation EGFR pathway. Importantly, I have 
observed the upregulation of the EGFR signalling pathway in pancreatic tumours (Table 3.7) 
suggesting that the downregulation of GALNT1 might have not influenced the pathway in 
PDAC.  
As the mechanism of action of GALNT1 in pancreatic cancer is still unclear; future studies to 
underscore its roles in pancreatic cancer are required.  
Heparan sulfate 3-O-sulfotransferase (HS3ST4) 
In this study the downregulation of HS3ST4 in pancreatic tumours was observed (Table A10). 
While no work has been done on HS3ST4 in pancreatic cancer cells, a study in breast tumours 
has linked its underexpression to metastasis.  Fernandez and colleagues showed that HS3ST4 
was underexpressed (8-fold) in 70% metastatic breast tumours and a more than 30-fold 
underexpression in 90% metastasis (Fernández-Vega et al., 2015) suggesting that the 
downregulation of HS3ST4 might play a role in enhancing metastasis and it might serve as a 
prognostic biomarker.  
HS3ST4 encodes the enzyme heparin sulphate D-glucosaminyl 3-O- sulfotransferase 4. It 
functions as a receptor for herpes simplex virus 1 (HSV1) and thus plays an inducing role in 
HSV1 pathogenesis (Fernández-Vega et al., 2015). Its role in pancreatic tumorigenesis is yet 
to be ascertained. 
The downregulation observed in breast (Fernández-Vega et al., 2015) and pancreatic tumours 
(Table 3.9) is indicative that HS3ST4 might be required to prevent metastasis. Drawing from 
the observations of Fernandez and colleagues, it would be interesting to study the effects of 
overexpression of HS3ST4 in tumours as it might anti-metastasis results.  
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Solute carrier family 15 member 4 (SLC15A4) 
I observed the downregulation of SLC15A4 in pancreatic tumours (Table A10). This appears 
to be the first study that identifies the expression of SLC15A4 in PDAC. Although little is 
known about the function of SLC15A4 in carcinogenesis, it has been identified to play a role 
in innate immune response via toll-like receptor 9 and NOD1 (Sasawatari et al., 2011). This 
suggests that its downregulation in pancreatic tumours might negatively affect innate immune 
response during tumorigenesis. SLCI5A4 is a member of the family of solute carriers known to 
be intrinsic membrane transproteins. SLCI5A4 transports oligonucleotides from the lysosome 
to the cytosol (Blasius et al., 2010; Kobayashi et al., 2014). This transport is crucial for immune 
response against pathogens (Crotzer and Blum, 2008). The impairment of this transport by the 
downregulation of SLC15A4 might result in the weakening of the immune system against 
cancerous cells. 
The role of SLC15A4 is not clearly defined in cancer. Other studies have linked it to the 
activation of the immune response. This study showed its downregulation in pancreatic 
tumours but not in normal tissues which might impair immune function during carcinogenesis. 
Future studies to investigate its role in pancreatic tumorigenesis might prove useful.  
Tetraspanin (TSPAN7) 
In this study, I observed the underexpression of TSPAN7 in pancreatic tumours (Table A10) 
and I hypothesize it might have a role in inhibiting tumorigenesis. This hypothesis is supported 
by Cheong and colleagues who showed that the overexpression of TSPAN7 in multiple 
myeloma patients was associated with better patient outcomes in up to 50% of patients (Cheong 
et al., 2015). Furthermore, in renal cell carcinoma patients the overexpression of TSPAN7 was 
associated with good outcome and disease-free survival (Wuttig et al., 2012). This suggests 
that its overexpression might increase patient survival whereas its underexpression may 
decreases it. 
TSPAN7 (also known as CD231, TM4SF2 and TALLA-1) belongs to a family of tetraspanins 
which are integral membrane proteins associated with an array of biological processes 
including the regulation of cell development, growth, and migration. Some cancer studies have 
identified the anti-metastatic role of the overexpression of TSPAN7. Studies in pancreatic 
cancer is necessary to elucidate its role in PDAC and maybe corroborate findings from other 
cancer studies. 
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4.6 Necrosis as a prognostic marker in pancreatic cancer 
The RT2 Human CancerPathway PCR Profiler array enabled us compare gene expression 
profiles in tumour tissues to those of the pancreatic cell line, MIA PaCa-2. Pathway analysis 
(using REACTOME software) of dysregulated genes show the upregulation of necrotic 
pathways in tumour tissues only indicating necrosis. This upregulation was not observed in the 
pancreatic cancer cell line- MIA PaCa-2. As this upregulation was observed in stage I tumour 
tissues, necrosis might be an indicator of PDAC induction. Hiraoka and colleagues observed 
the presence of tumour necrosis in about 62% of pancreatic tumours after histological analysis. 
They concluded that tumour necrosis in pancreatic tissues was a fast, simple, and efficient way 
of predicting postoperative out comes in pancreatic cancer patients (Hiraoka et al., 2010).  
Necrosis is a type of cell death in which cells expand and burst giving off their contents to the 
tissue microenvironment. This process contrasts with apoptosis (programmed cell death) in 
which a dying cell shrinks and is devoured by neighbouring cells. Necrosis has recently been 
recognized as a tightly regulated process occurring under certain conditions (Galluzzi and 
Kroemer, 2008; Zong and Thompson, 2006). Unlike other types of programmed cell death such 
as autophagy and apoptosis, necrosis causes the release of proinflammatory indicators into the 
surrounding tissue microenvironment (Galluzzi and Kroemer, 2008; Grivennikov et al., 2010; 
White et al., 2010). This release consequently leads to the recruitment of the immune 
inflammatory cells, which act to remove necrotic debris in damaged tissue. However, during 
carcinogenesis these inflammatory cells can be pro-tumorigenic as they can induce cellular 
proliferation, angiogenesis and tumour invasion. Furthermore, necrotic cells release regulatory 
factors like the interleukin-1α, that can induce adjoining cells to proliferate 
uncontrollably(Grivennikov et al., 2010).  
Taken together observations from this study and those of Hiraoka et al., suggest that the 
presence of tumour necrosis may play a role in the induction and advancement pancreatic 
tumorigenesis and may be used as a prognostic marker. Furthermore, targeting tumour necrosis 
may prove beneficial therapeutically in the management of pancreatic cancer. 
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4.7 The immune system is active during PDAC 
Having analysed the18 significantly upregulated proteins in tumour samples using 
REACTOME it appears that several immune system pathways are upregulated. This suggests 
that the immune system is activated during PDAC. 
This present study corroborates others in which the immune system is observed to be activated 
during carcinogenesis.  The other studies have observed that the innate and adaptive immune 
responses are both active having crucial and diverse effects on cancer cells (Balkwill and 
Mantovani, 2012). The innate immune system is primarily involved in removal of dead cells 
and wound healing while the adaptive one identifies and aid in the destruction of infectious 
foreign agents. These functions are carried out by different types of immune inflammatory cells 
some of which are crucial sources of growth and angiogenic factors (as described above). These 
factors are required and thus recruited for tumour progression (Egeblad et al., 2010; Johansson 
et al., 2008; Mantovani, 2010).   
To function effectively against cancer cells, the immune system requires mature dendritic cells, 
CD8 T cells, activated macrophages, T-helper 1 cells and natural killer cells. Cancer cells have 
developed several mechanisms to avoid recognition by the immune system (Amedei et al., 
2014). Avoiding immune recognition and destruction has been identified as an emerging 
hallmark of cancer (Hanahan and Weinberg, 2000). Mechanisms used by tumour cells to avoid 
recognition include the secretions of factors that suppress the immune system such as VEGF. 
Importantly, in this study I have observed the overexpression of components of the VEGF 
signalling pathway in pancreatic tumours indicating VEGF might be exerting 
immunosuppressive abilities on pancreatic cancer cells (Table 3.3). Other mechanisms include; 
interfering with MHC class II antigen presentation and expressing ligands of the immune 
system like PD-L1(Amedei et al., 2014).  
In this study, the MHC II antigen presentation pathway was observed to be downregulated and 
suggest tumour cells may evade the immune system via this mechanism (Table 3.5). MHC 
class II molecules are present in only antigen presenting cells like B cells and dendritic cells 
which are crucial in the initiation of immune responses. The downregulation of the MHC class 
II antigen presentation pathway has been observed to enable tumours avoid identification and 
eradication by the immune system (Pandha et al., 2007).  
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Interestingly, the MHC II antigen presentation pathway was also enriched by upregulated 
proteins (Table 3.15). This enrichment is by the cathepsins- a family of proteases. Cathepsin S 
(a member of the cathepsin family) plays a role in tumour invasion, metastasis and in the 
regulation of MHC II (Beers et al., 2005; Tan et al., 2013). Thus, an upregulation of cathepsin 
S result to a downregulation of the MHC class II protein. This downregulation in turn may 
provide a way for tumour to evade the immune system as described above. The overexpression 
of cathepsin S in pancreatic tumours might inhibit the expression and function of MHC II as 
they are known regulators.  
This study showed the activation of the immune response during PDAC. I observed some of 
the mechanisms reported in the literature as to how tumours evade the immune system. 
Targeting these mechanisms might prove beneficial for the development of immune-based 
therapeutic strategies for PDAC treatment.  
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CONCLUSION 
PDAC is a lethal disease and early detection by identifying of diagnostic biomarkers and 
further understanding of the disease is critical. The present study has identified three potential 
biomarkers-ANGPTL4, P27 and JUP for PDAC. Their significant upregulation in pancreatic 
tumours but not in corresponding normal tissues and their abilities to be secreted into the 
bloodstream, may make them potential candidates for use in diagnosis tests. The implication 
of this is that these candidate markers may be useful in the early diagnosis of asymptomatic 
PDAC. Even though these biomarkers could be overexpressed in other cancers such as the 
upregulation of JUP in testicular germ cell tumours, the combination of 3 of them may provide 
increased sensitivity and specificity to PDAC. Future studies using high throughput methods 
like ELISA and mass spectrometry with a much larger sample amount should be done to 
confirm these novel potential biomarkers. Also, it would be interesting to observe the 
expression patterns of these potential biomarkers at different stages of PDAC as this might 
provide useful information of their probable in prognosis too. 
This study identified novel genetic variants SPARC, ZFHX3, TGM2 and COLIA1 predicted to 
result in loss of gene function. These genes have been observed to play anti-tumorigenic roles, 
thus their loss of function may enable tumorigenesis. Future validation studies utilizing a larger 
sample size may be crucial to validating the occurrence of these variants in PDAC. It might 
also be important to investigate extensively the roles of these genes in pancreatic 
tumorigenesis.  
The dysregulation of several signalling pathways such as IGF/MAPK, Integrin, and Ras 
signalling pathway in tumours were observed in this study. These dysregulated pathways may 
induce cellular proliferation, survival and migration which results in tumorigenesis. Thus, they 
might possess capabilities of being good targets in pancreatic cancer treatment. Future studies 
in investigating the dysregulation of these pathways at different stages of PDAC is pertinent n 
elucidating their roles.  
This study has identified 5 genes downregulated in pancreatic tumours. Other studies indicate 
these genes may play tumour suppressive roles and that their upregulation might be crucial to 
inhibit tumorigenesis. It is however crucial that the downregulation of these genes be validated 
using a much larger sample amount. Future studies targeting these genes for therapy might 
prove helpful. 
87 
 
Furthermore, the upregulation of necrotic pathways in pancreatic tumours observed in this 
study might be indicative of poor prognosis. Interestingly, these pathways were observed only 
in pancreatic tumours but not in their corresponding normal tissues and the MIA PaCa-2 cell 
line. Presence or absence of necrosis in tumours might provide a way of predicting prognosis 
of early stage PDAC patients.  
Finally, the upregulation of immune system pathways in pancreatic tumours observed in this 
study, suggest the activation of immune response. However, cancer cells seem to develop 
mechanisms to circumvent immune detection and destruction. This study identified some of 
these mechanisms such as the upregulation of the VEGF signalling pathway. Future studies, 
targeting these mechanisms may enable the immune system plays its role in the eradication of 
tumour cells. 
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APPENDICES 
Table A1: Genetic biomarkers of Pancreatic cancer 
Potential 
biomarker 
Sample(s) 
used 
Discovery 
method(s) used 
Indicator Function(s) Reference(s) 
K-ras Tumor Global genomic 
analyses 
Gain-of-
function 
mutation 
frequently 
occurs in 
pancreas 
cancer. 
Performs a 
critical function 
in cell growth 
and signalling 
(Jones et al., 
2008a) 
miR-210 Plasma qRT-PCR, 
quantified using 
TaqMan 
MicroRNA Assays 
Plasma levels 
are elevated in 
pancreatic 
cancer 
Implicated in 
several cellular 
mechanisms 
(Ho et al., 
2010) 
MUCI Tissue Tissue microarrays Pam4 reactive 
MUC1 
expressed in 
pancreatic 
cancer 
Hydrates cell 
surfaces and 
protects against 
microorganisms. 
(Gold et al., 
2007) 
CA 19-9 Serum 
Blood 
Immunoradiometric 
assay, Enzyme 
immunoassay 
Serum levels 
are elevated in 
pancreatic 
cancer 
Functions in 
adhering cells to 
endothelium 
(Tian et al., 
1992) 
(Molina et 
al., 1990) 
Htert Pancreatic 
juice 
Tissue 
Tissue microarray Overexpressed 
in pancreatic 
cancer tissue 
samples 
Provides 
information on 
the manufacture 
of a component 
of the enzyme- 
telomerase 
(Hashimoto 
et al., 2008) 
L1-CAM Tissue Tissue microarray Overexpressed 
in pancreatic 
cancer tissue 
samples 
Provides 
information on 
the manufacture 
of the L1 
protein that can 
be found on the 
surfaces of 
neurons 
(Ben et al., 
2010) 
B7-H3 Tissue qRT-PCR Significantly 
upregulated in 
pancreatic 
cancer 
Function 
unclear 
(Loos et al., 
2009) 
PALB2 Tissue Exomic sequencing Germline 
mutation 
Encodes a 
protein that 
functions in 
genome 
maintenance 
(Jones et al., 
2009) 
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Table A2: Metabolomic biomarkers of pancreatic cancer 
Potential 
biomarker 
Sample(s)used Discovery 
method(s) 
used 
Indicator Function(s) Reference(s) 
Dimethylamine Plasma Pattern 
recognition 
techniques 
applied to (1)H 
nuclear 
magnetic 
resonance 
spectra 
Plasma 
levels 
elevated in 
pancreatic 
cancer 
Carcinogen (Zhang et al., 
2012) 
Acetone Plasma Pattern 
recognition 
techniques 
applied to (1)H 
nuclear 
magnetic 
resonance 
spectra 
Plasma 
levels 
elevated in 
pancreatic 
cancer 
 (Zhang et al., 
2012) 
3-hydroxybutyrate Plasma Pattern 
recognition 
techniques 
applied to (1)H 
nuclear 
magnetic 
resonance 
spectra 
Plasma 
levels 
reduced in 
pancreatic 
cancer 
 (Zhang et al., 
2012) 
Lactate Plasma Pattern 
recognition 
techniques 
applied to (1)H 
nuclear 
magnetic 
resonance 
spectra 
Plasma 
levels 
reduced in 
pancreatic 
cancer 
Critical 
source of 
energy 
(Zhang et al., 
2012) 
Citrate Plasma Pattern 
recognition 
techniques 
applied to (1)H 
nuclear 
magnetic 
resonance 
spectra 
Plasma 
levels 
reduced in 
pancreatic 
cancer 
Critical 
metabolite in 
the TCA 
cycle 
(Zhang et al., 
2012) 
3-
hydroxyisovalerate 
Serum (1)H nuclear 
magnetic 
resonance 
spectra 
Serum 
levels 
reduced in 
pancreatic 
cancer 
Suppresses 
the 
breakdown 
of protein, 
and the 
damage of 
cells after 
exercising 
(OuYang et 
al., 2011) 
Trimethyamine-N-
oxide 
Serum (1)H nuclear 
MR spectra 
Serum levels 
reduced in 
PC 
 (OuYang et 
al., 2011) 
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Table A3: Proteomic biomarkers of pancreatic cancer 
Potential 
biomarker 
Sample(s) 
used 
Method(s) used Indicator Function(s) Reference(s) 
Vimentin Serum, 
Pancreatic 
cancer 
cell line 
2-D PAGE, Western 
blotting 
Overexpressed 
in pancreatic 
cancer cell line 
(Panc-1) 
Anchorage and 
positioning of 
organelles within 
the cytosol 
(Hong et al., 
2006) 
Rad51 Tissue, 
Pancreatic 
cancer 
cell lines 
3-D cell culture, 
Western blotting 
Overexpressed 
in pancreatic 
cancer tissue 
samples 
Functions in the 
repair of DNA 
double strands 
break 
(Maacke et 
al., 2000) 
Osteopontin Serum Surface-enhanced laser 
desorption and 
ionization (SELDI) 
protein chip mass 
spectrometry 
Elevated levels 
in serum of 
pancreatic 
cancer 
pantients 
Multiple roles in 
the remodelling 
of the bone and 
in the immune 
system 
(Koopmann 
et al., 2004) 
DEAD-box 
protein 48 
Serum 2-D PAGE, 
Immunoblot analysis, 
liquid chromatography-
electrospray ionization 
tandem mass 
spectrometry 
Expressed in 
serum of 
pancreatic 
cancer patients 
Role in RNA 
metabolism 
(Xia et al., 
2005) 
Calreticulin Serum, 
Pancreatic 
cancer 
cell line 
2-D PAGE, Western 
blotting 
Expressed in 
tissue of 
pancreatic 
cancer patients 
Multiple roles 
including 
transcription 
regulation 
(Hong et al., 
2004) 
Anti-thrombin-III Pancreatic 
juice 
2-D PAGE, MALDI-
TOF-MS 
Upregulated in 
pancreatic 
juice of 
pancreatic 
cancer patients. 
Functions in 
inhibiting the 
coagulating of 
lysed thrombin 
and factor Xa 
(Zhou et al., 
2007) 
Lipocalin 2 Pancreatic 
juice 
1-D gel 
electrophoresis, liquid 
chromatography 
tandem mass 
spectrometry (LC-
MS/MS). 
Overexpressed 
in pancreatic 
juice of 
pancreatic 
cancer patients 
Functions in 
innate immunity 
response and as a 
growth factor 
(Gronborg et 
al., 2004) 
PAP-2 Pancreatic 
juice 
1-D gel 
electrophoresis, liquid 
chromatography 
tandem mass 
spectrometry (LC-
MS/MS). 
Overexpressed 
in pancreatic 
juice of 
pancreatic 
cancer patients 
Stimulation of 
macrophage 
activity and in 
the modulation 
of the 
inflammatory 
environment in 
pancreatitis 
(Gronborg et 
al., 2004) 
Cytokeratin 18 
 
Tissue, 
Plasma 
Enzyme-linked 
immunoassays 
Plasma levels 
are elevated in 
pancreatic 
cancer 
Component of  
the intracellular 
cytoskeleton 
(Dive et al., 
2010) 
Serum REG4 Serum Enzyme-linked 
immunosorbent assay 
(ELISA). 
Serum levels 
are elevated in 
pancreatic 
cancer 
Maintains CHO 
recognition 
activity even in 
an acidic 
condition 
(Takayama 
et al., 2010) 
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Serine 
proteinase-
2(PRSS2) pre 
protein 
Pancreatic 
juice 
2-D PAGE, Mass 
spectrometry, qRT-
PCR 
Upregulated in 
pancreatic 
juice in 
pancreatic 
cancer 
Protein precursor 
of PRSS2 
PRSS2 is 
involved in 
cleaving peptide 
bonds where 
serine functions 
as the 
nucleophillic 
amino acid at the 
active site of the 
enzyme 
(Gao et al., 
2010) 
Pancreatic lipase 
related protein-1 
(PLRP1) 
Pancreatic 
juice 
2-D PAGE, Mass 
spectrometry, qRT-
PCR 
Upregulated in 
pancreatic 
juice in 
pancreatic 
cancer 
Function unclear (Gao et al., 
2010) 
Mucins- MUC2, 
MUC4, 
MUC5B,MUC5C 
Tissue, 
Pancreatic 
cancer 
cell line 
Immunohistochemistry, 
in situ hybridization 
Blood levels 
elevated 
Formation of 
chemical 
barriers, 
lubrication and 
involved in cell 
signalling 
(Swartz et 
al., 2002) 
S100P Tissue, 
Pancreatic 
cancer 
cell line 
Far Western screening 
and in vitro interaction 
assays 
Overexpression 
in pancreatic 
cancer 
Calcium binding 
protein 
(Dowen et 
al., 2005) 
CEA Blood Radioimmunoassays Overexpression 
in pancreatic 
cancer 
Involved in the 
adhesion of cells 
(Molina et 
al., 1990) 
CA-50 Blood Time-resolved 
flourescence 
immunoassay, 
immunoradiometric 
assay 
Overexpression 
in pancreatic 
cancer 
 (Molina et 
al., 1990) 
(Haglund et 
al., 1987) 
TROP2 Tissue Immunohistochemistry Overexpression 
in tissue 
samples of 
pancreatic 
cancer patients 
Transmembrane 
protein- function 
unclear 
(Fong et al., 
2008) 
CDCP1 Tissue, 
Pancreatic 
cancer 
cell line 
Western blotting, Cell 
migration and Matrigel 
invasion assay, ECM 
degradation assays, 
Immunocytochemical 
staining 
Overexpressed 
in pancreatic 
cancer 
regulates anoikis 
resistance, Cell 
migration and 
the degradation 
of ECM 
(Miyazawa 
et al., 2010) 
N-acetyl 
glycoprotein 
Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
elevated in 
pancreatic 
cancer 
 (Zhang et al., 
2012) 
VLDL Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
elevated in 
pancreatic 
cancer 
Body’s transport 
mechanism for 
lipids 
(Zhang et al., 
2012) 
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HDL Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
reduced in 
pancreatic 
cancer 
Protection 
against heart 
disease by 
reverse 
transporting 
cholesterol 
(Zhang et al., 
2012) 
LDL Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
reduced in 
pancreatic 
cancer 
Transport of 
cholesterol to the 
cells 
(Zhang et al., 
2012) 
Alanine Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
reduced in 
pancreatic 
cancer 
Helps in protein 
production, 
neurotransmitters 
formation and 
the proper 
functioning of 
the nervous 
system 
(Zhang et al., 
2012) 
Glutamate Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
reduced in 
pancreatic 
cancer 
Involved in 
normal brain 
functioning and 
in the CNS 
(Zhang et al., 
2012) 
Glutamine Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
reduced in 
pancreatic 
cancer 
Source of 
cellular energy, 
production of 
proteins, 
regulating acid-
base balance 
(Zhang et al., 
2012) 
Histidine Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
reduced in 
pancreatic 
cancer 
Transport of 
metals and 
enhances 
calcium 
absorption 
(Zhang et al., 
2012) 
Isoleucine Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
reduced in 
pancreatic 
cancer 
Source of energy (Zhang et al., 
2012) 
Lysine 
 
Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
reduced in 
pancreatic 
cancer 
Helps in bone 
formation, 
collagen 
formation, 
calcium 
absorption in the 
intestine 
(Zhang et al., 
2012) 
Valine Plasma Pattern recognition 
techniques applied to 
(1)H nuclear magnetic 
resonance spectra 
Plasma levels 
reduced in 
pancreatic 
cancer 
Prevents muscle 
breakdown, 
helps in the 
functioning of 
the nervous 
system 
(Zhang et al., 
2012) 
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Table A4: Circulating Endothelial Cells as biomarkers of Pancreatic cancer 
Potential 
biomarker 
Sample(s) 
used 
Discovery method(s) 
used 
Indicator Function(s) References 
Circulating 
endothelial 
cells 
Blood Flow cytometry, 
Immunohistochemistry, 
ELISA 
Blood 
levels 
increased 
in 
pancreatic 
cancer 
Endothelial 
cells 
maintain the 
strength of 
the vascular 
membrane 
and its 
permeability 
(Sabbaghian 
et al., 2010) 
 
 
Table A5: Salivary Transcriptomic Markers of Pancreatic cancer 
Potential 
biomarker 
Sample(s) 
used 
Discovery 
method(s) 
used 
Indicator Function(s) References 
Salivary 
transcriptomic 
biomarkers 
(MBD3L2, 
ACRV1, 
DMPM1, 
KRAS) 
Saliva Affymetrix 
array, qPCR 
Expressed in 
pancreatic 
cancer 
Varying (Zhang et al., 
2010) 
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Figure A1: Samples passed all tests (Reverse transcription control, Genomic DNA contamination and 
PCR array reproducibility). The Inquiry indicated on the PCR array reproducibility test was due to the 
average CT of all samples exceeding 22. However, due to differences in sensitivity of real time machines 
this can be acceptable provided values did not vary more than 2 cycles between the arrays which was 
the case in this experiment. 
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Figure A2: The software automatically did normalization. The software chooses the most stable 
housekeeping gene. The CT values were geometrically averaged and used for normalization. B2M was 
the most stable. 
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Figure A3: Array plate layout showing fold changes of Group 1(a) and Group 2(b) genes. Genes marked 
with “A” indicate that the gene is observed to relatively low in one sample but relatively high in the 
other. 
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Table A6: List of genes uniquely upregulated and downregulated in Group 1 and 2 
Upregulated Down-regulated 
Group 1 Group 2 Group 1 Group 2 
SNAI2 FGF2 ACLY IGFBIP5 
IGFBP3 CDC20 CASPD IGFBIP3 
CFLAR HPRT1 ARNT IGFBIP7 
TINF2 VEGFC VEGFC SNAI2 
KDR ATPSA1 ACSL4 FLT1 
SLC2A1 PINX1 EPO TBX2 
IGFBP7 STMN1  LPL 
XIAP UQCRFS1 TEK 
IGFBP5 SKP2 KDR 
ETS2 MK167 CCND2 
 RPLPO CCL2 
AURKA TERF1 
NOL3 SERPINB2 
ARNT CDH2 
DKC1 SOX10 
ADM FOXC2 
DDIT3 CCND3 
DDB2 ANGPT2 
BIRC3 FASLG 
PFKL ETS2 
TERF21P SNAI1 
TNKS XIAP 
HMOX1 BMI1 
 DSP 
HGDC 
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Table A7: Showing top 10 molecular functions enriched by upregulated genes.  
GO ID Molecular 
function 
Homo 
sapiens 
(Ref) 
Client 
input 
Expected Fold 
enrichment 
p-value 
GO:0048365 Rac GTPase 
binding 
40 31 9.26 3.35 3.69E-05 
GO:0017048 Rho GTPase 
binding 
80 50 18.52 2.7 2.62E-06 
GO:0017016 Ras GTPase 
binding 
254 121 58.8 2.06 1.48E-09 
GO:0031267 Small GTPase 
binding 
272 131 62.97 2.08 7.78E-09 
GO:0051020 GTPase binding 295 143 68.29 2.09 3.20E-12 
GO:0019899 Enzyme binding 1750 762 405.12 1.88 2.71E-59 
GO:0005515 Protein binding 1075 3422 2488.85 1.37 4.63E-160 
GO:0005488 Binding 14268 4057 3303.03 1.23 1.27E-130 
GO:0050840 Extracellular 
matrix binding 
53 36 12.27 2.93 7.23E-05 
GO:0005518 Collagen binding 65 40 15.05 2.66 1.71E-04 
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Table A8: Showing top 10 cellular components enriched by upregulated genes.  
GO ID Cellular 
component 
Homo 
sapiens 
(Ref) 
Client 
input 
Expected Fold 
enrichment 
p-value 
GO:0005840 Ribosome 119 54 27.55 1.96 3.01E-04 
GO:1990904 Ribonucleoprotein 
complex 
335 110 77.55 1.42 1.61E-02 
GO:0032991 Macromolecular 
complex 
1454 415 336.6 1.23 5.98E-04 
GO:0031012 Extracellular 
matrix 
185 73 42.83 1.7 9.29E-04 
GO:0005794 Golgi apparatus 130 50 30.09 1.66 3.19E-02 
GO:0043226 Organelle 2656 765 614.86 1.24 1.16E-08 
GO:0005829 Cytosol 328 126 75.93 1.66 4.30E-06 
GO:0005737 Cytoplasm 2088 664 483.37 1.37 5.75E-15 
GO:0005622 Intracellular 4020 1204 930.63 1.29 1.86E-20 
GO:0044464 Cell part 4115 1222 952.62 1.28 1.42E-19 
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Table A9: Showing top 10 protein classes enriched by upregulated genes.  
Protein class Homo 
sapiens 
(Ref) 
Client 
input 
Expected Fold 
enrichment 
p-value 
Nucleic acid binding 2367 2706 547.96 1.29 5.83E-10 
Enzyme modulator 1353 449 313.22 1.43 8.68E-12 
Transferase 1164 342 269.47 1.27 1.35E-03 
RNA binding protein 887 308 205.34 1.50 9.59E-10 
Cytoskeletal protein 778 248 180.11 1.38 1.17E-04 
G-protein modulator 481 201 111.35 1.81 1.27E 
Actin-family 
cytoskeletal protein 
389 152 90.05 1.69 2.31E-07 
Ribosomal protein 228 90 52.78 1.71 3.45E-04 
Non-motor actin 
binding protein 
179 85 41.44 2.05 3.40E-07 
Guanyl-nucleotide 
exchange factor 
179 79 41.44 1.91 2.38E-05 
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Figure A4: Bar chart showing top transcription factors in which our upregulated genes are enriched. 
Percentages of genes enriched are shown on top of each bar. Yellow dots indicate p-value of less than 
0.001 and red indicates p-values of 0.05. 
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Figure A5: Bar chart showing top clinical phenotypes in which our upregulated genes are enriched. 
Percentages of genes enriched are shown on top of each bar. Yellow dots indicate p-value of less than 
0.001 and red indicates p-values of 0.05. 
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Table A10: Showing functional enrichment analysis of downregulated genes. 
CXXC4 CXXC finger 4 
Biological process 
embryonic axis specification, regionalization, cell surface receptor linked 
signal transduction, zygotic determination of dorsal/ventral axis, pattern 
specification process, axis specification, embryonic pattern 
specification, dorsal/ventral axis specification, dorsal/ventral pattern 
formation, negative regulation of signal transduction, negative regulation of 
cell communication, Wnt receptor signalling pathway, regulation of Wnt 
receptor signalling pathway, negative regulation of Wnt receptor signalling 
pathway, 
Cellular component cytoplasmic membrane-bounded vesicle, cytoplasmic 
vesicle, vesicle, membrane-bounded vesicle, 
Molecular function 
DNA binding, zinc ion binding, protein domain specific binding, PDZ 
domain binding, ion binding, cation binding, metal ion binding, transition 
metal ion binding, 
Protein class Zinc finger, CXXC-type,  
Pathway Wnt signalling pathway,  
GALNT1 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 13 (GalNAc-T13); UDP-N-acetyl-alpha-
D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 
(GalNAc-T1) 
Biological process 
protein amino acid glycosylation, protein amino acid O-linked 
glycosylation, glycoprotein metabolic process, glycoprotein biosynthetic 
process, peptidyl-serine modification, peptidyl-threonine 
modification, protein amino acid O-linked glycosylation via serine, protein 
amino acid O-linked glycosylation via threonine, biopolymer 
glycosylation, glycosylation, 
Cellular component extracellular region, Golgi apparatus, integral to membrane, intrinsic to 
membrane, perinuclear region of cytoplasm, 
Molecular function 
polypeptide N-acetylgalactosaminyltransferase activity, calcium ion 
binding, sugar binding, acetylgalactosaminyltransferase activity, manganese 
ion binding, carbohydrate binding, ion binding, cation binding, metal ion 
binding, transition metal ion binding, 
Protein class Ricin B lectin, Glycosyl transferase, family 2 
Pathway O-Glycan biosynthesis 
HS3ST4 Heparan sulphate (glucosamine) 3-O-sulfotransferase 4 
Biological process proteoglycan metabolic process, sulfur metabolic process, glycoprotein 
metabolic process, heparan sulphate proteoglycan metabolic process, 
Cellular component  Golgi apparatus, integral to membrane, intrinsic to membrane, 
Molecular function 
sulfotransferase activity, [heparan sulphate]-glucosamine 3-sulfotransferase 1 
activity, transferase activity, transferring sulfur-containing groups, heparan 
sulphate sulfotransferase activity, 
Protein class Sulfotransferase 
SLC15A4 solute carrier family 15, member 4 
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Biological process oligopeptide transport, protein localization, protein transport, peptide 
transport, establishment of protein localization, 
Cellular component 
lytic vacuole, lysosome, lysosomal membrane, vacuole, vacuolar 
membrane, integral to membrane, organelle membrane, intrinsic to 
membrane, vacuolar part, 
Molecular function 
peptide transporter activity, symporter activity, solute:cation symporter 
activity, solute:hydrogen symporter activity, peptide:hydrogen symporter 
activity, proton-dependent peptide secondary active transmembrane 
transporter activity 
Protein class TGF-beta receptor, type I/II extracellular region, TGF-beta receptor, type I/II 
extracellular region. 
TSPAN7 Tetraspanin 7 
Biological process 
protein amino acid glycosylation, protein amino acid N-linked 
glycosylation, glycoprotein metabolic process, glycoprotein biosynthetic 
process, biopolymer glycosylation, glycosylation, 
Cellular component 
plasma membrane, integral to plasma membrane, integral to 
membrane, intrinsic to membrane, intrinsic to plasma membrane, plasma 
membrane part, 
Protein class Tetraspanin, subgroup, Tetraspanin, Tetraspanin, conserved site, 
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Table A11: Top 5 molecular functions enriched in JUP PPI network 
Pathway ID Pathway description Count in gene set False discovery rate 
GO:0008013 Beta-catenin binding 8 7.87E-16 
GO:0045295 Gamma-catenin 
binding 
4 3.06E-08 
GO:0005515 Protein binding 10 1.94E-03 
GO:0086083 Cell adhesive protein 
binding involved in 
bundle of His cell-
Purkinje myocyte 
communication 
2 2.7E-03 
GO:0045294 Alpha-catenin binding 2 5.55E-03 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
 
Figure A6: Pie chart showing pathways associated with the observed genetic variants. The number of 
variants enriched in each pathway is seen in parenthesis.  
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Figure A7: Pie chart showing diseases associated with the observed genetic variants. The number of 
variants enriched in each disease is seen in parentheses.  
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Table A12: Top 5 molecular functions in which the ANGPTL4 PP1 network is enriched.  
Pathway ID Pathway description Count in gene set False discovery rate 
GO: 0000989 Transcription factor 
activity 
8 8.09E-08 
GO: 0008134 Transcription factor 
binding 
7 3.48E-07 
GO: 0003712 Transcription cofactor 
activity 
7 1.47E-06 
GO: 0035257 Nuclear hormone 
receptor binding 
5 1.47E-06 
GO: 0033613 Activating 
transcription factor 
binding 
4 6.05E-06 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
Table A13: Top 5 molecular functions in which the CDKN1B/p27 PP1 network is enriched.  
Pathway ID Pathway description Count in gene set False discovery rate 
GO: 0016538 Cyclin-dependent 
protein 
serine/threonine kinase 
regulator activity 
4 1.11E-06 
GO: 0004693 Cyclin-dependent 
protein 
serine/threonine kinase 
activity 
4 2.21E-06 
GO: 0016301 Kinase activity 7 1.69E-05 
GO: 0030332 Cyclin binding 3 4.42E-05 
GO: 0004672 Protein kinase activity 6 8.34E-05 
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Table A14: Showing patients used in study with relevant information 
Patient Patient number Age Gender Smoked Alcohol Crp 
levels 
Stage 
1 CHMBAD000009 62 Female No No ---- 1 
2 CHMBAD000031 69 Male Yes Yes ---- 1 
3 CHMBAD000066 41 Male Yes Yes 12 1 
4 CHMBAD000074 60 Male Yes Yes 279 1 
5 CHMBAD000091 62 Male Yes Yes ---- 1 
6 CHMBAD000096 52 Female No Yes 117 1 
7 CHMBAD000097 61 Female No No 23 1 
8 CHMBAD000118 67 Male Yes No 31 1 
9 CHMBAD000120 56 Male Yes Yes 116 1 
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Table A15: List of kits used with their manufacturers and catalogue numbers. 
Kit Manufacturer and Catalogue number 
AllPrep DNA/RNA mini kit Qiagen 80201 
DNase Sigma-AMPDL IKT 
Bradford protein assay Bio-Rad 5000006 
RT2 First strand kit Qiagen 330401 
2X PCR Mastermix NEB M0207L 
Human Cancer PathwayFinder RT2 Profiler 
PCR array 
Qiagen 330231 PAHS-033Z 
SYBR green mix Qiagen 7540246 
Proteome profiler Human Oncology array kit RND systems ARY026 
JUP Primer assay Qiagen 330001 PPH07138F 
COPG Primer assay Qiagen 330001 PPH07138F 
TCIRG1 Primer assay Qiagen 330001 PPH09294A 
MRPL19 Primer assay Qiagen 330001 PPH09294A 
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Table A16: List of Instruments used with their manufacturers and catalogue numbers. 
Instrument Manufacturer and Catalogue number 
TissueRuptor Qiagen 9001272 
Nanodrop ND-1000 UV 
Electrophoresis tank Scieplus VG Sys 30020529 
Power supply Sigma techware PS250-2 
Spectrophotometer Shimadza UV-160A 
Chemi-Doc Bio-Rad Gel Doc XR+ 
8-well Multi pipette Integra 4624 
Real-time cycler machine Roche LC-480 
Room temperature centrifuge Heraeus T5003280 
4°C centrifuge Eppendorf 22331 
96-well plate centrifuge Grant-bio LMC-3000 
96-well plate 4titude-4ti-0955 
PCR machine Geneamp PCR system 2400 
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Table A17: List of software used with the link to their websites. 
Software used Website  
Wvision Quickspots www.wvision.com/Quickspots.html 
Uniprot www.uniprot.com 
FunRich www.funrich.org 
Panther www.pantherdb.org 
GeneMania www.genemania.com 
Gene Ontology Geneontology.org 
DAVID DAVId.ncifcrf.gov 
Qiagen RT2 Profiler PCR array software pcrdataanalysis.sabiosciences.com 
Reactome www.reactome.org 
Ingenuity Pathway Analysis (IPA)- 
Biomarker filtering 
www.ingenuity.com/ipa 
Ingenuity Variant Analysis (IVA) www.qiagenbioinformatics.com/products/ingenuity-
variant-analysis/ 
Morpheus https://software.broadinstitute.org/morpheus/ 
CLC genomics workbench www.qiagenbioinformatics.com/products/clc-
genomics-workbench 
REST software http://www.wzw.tum.de/gene-quantification/ 
STRING analysis tool http://string-db.org/ 
Pancreatic cancer database http://pancreaticcancerdatabase.org/publications.php 
NCBI https://www.ncbi.nlm.nih.gov/pubmed 
MEDICALC https://www.medcalc.org/calc/diagnostic_test.php 
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Table A18: List of Reagents/Chemicals used with their manufacturers and catalogue numbers. 
Reagent/Chemical Manufacturer and Catalogue number 
RNAlater Qiagen 76106 
Igepal Sigma l3021 
Sodium chloride Ace 29249 
Sodium dodecyl sulphate VWR Chemicals 442444H 
Sodium deoxy cholate BDH 43035 
Aprotinin Sigma A6279 
PMSF Sigma P7626 
Trizma base Sigma T1503-500G 
FBS Biowest S1815-500 
Penicillin-Streptomycin Sigma P433-20ml 
DMEM Sigma D5796-500ml 
Trypsin-EDTA Sigma T3924-10ml 
BSA Armour laboratories CH3170 
RNase-free water Qiagen 129317 
Formaldehyde Sigma F8775-50 
Ethidium bromide Sigma E1510 
DNA Molecular weight marker Thermo scientific SM1333 
RNA loading dye Thermo scientific 
6X DNA loading dye Thermo scientific R0611 
Agarose Lonza 50004 
TBE Sigma T4415 
MOPS Sigma 69947-100G 
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